[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 224
1. Lodish MB, Stratakis CA: RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther; 2008 Apr;8(4):625-32
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
  • Genotype-phenotype correlations exist that help predict the presence of other associated endocrine neoplasms as well as the timing of thyroid cancer development.
  • MTC represents a promising model for targeted cancer therapy, as the oncogenic event responsible for initiating malignancy has been well characterized.
  • The RET proto-oncogene has become the target for molecularly designed drug therapy.
  • Tyrosine kinase inhibitors targeting activated RET are currently in clinical trials for the treatment of patients with MTC.
  • This review will provide a brief overview of MTC and the associated RET oncogenic mutations, and will summarize the therapies designed to strategically interfere with the pathologic activation of the RET oncogene.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21 [16849420.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4 Suppl):S45-8 [17916518.001]
  • [Cites] Mini Rev Med Chem. 2006 Oct;6(10):1137-43 [17073714.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2795-802 [17019708.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):18-23 [17133107.001]
  • [Cites] Thyroid. 2005 Jun;15(6):531-44 [16029119.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):441-67 [15982921.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1105-13 [16162881.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):79-84 [16263812.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1139-48 [10699905.001]
  • [Cites] Hum Gene Ther. 2000 May 1;11(7):995-1004 [10811228.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):715-8 [10952773.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1426-31 [11245446.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5350-8 [11536047.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 21;294(4):813-7 [12061779.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):543-9 [12094241.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7284-90 [12499271.001]
  • [Cites] J Nucl Med. 2003 Jan;44(1):1-6 [12515868.001]
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):897-903 [12630912.001]
  • [Cites] Hum Gene Ther. 2003 Jul 1;14(10):971-82 [12869215.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):101-4 [12946481.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):197-211 [15013219.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14 [15240784.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6056-63 [15184865.001]
  • [Cites] Arch Surg. 1980 Feb;115(2):142-8 [7356828.001]
  • [Cites] Cell. 1985 Sep;42(2):581-8 [2992805.001]
  • [Cites] Br J Surg. 1986 Apr;73(4):278-81 [3697657.001]
  • [Cites] Lancet. 1988 Feb 20;1(8582):397-401 [2893198.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):432-6 [8293411.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579-83 [7906417.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):380-3 [8114940.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):237-47; discussion 247-50 [7916559.001]
  • [Cites] Science. 1995 Jan 20;267(5196):381-3 [7824936.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1613-9 [7532281.001]
  • [Cites] Ann Oncol. 1995 Jan;6(1):77-9 [7710986.001]
  • [Cites] Thyroid. 1996 Aug;6(4):305-10 [8875751.001]
  • [Cites] JAMA. 1996 Nov 20;276(19):1575-9 [8918855.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73 [9578814.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:104-12 [15650236.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):122-9 [15719378.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):172-83 [15719031.001]
  • [Cites] PLoS Biol. 2005 Apr;3(4):e123 [15769183.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] Drugs. 2006;66(4):449-75 [16597163.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1705-11 [16549819.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):564-74 [17019434.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Feb;16(2):239-49 [17243944.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2369-76 [17557949.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Jul;5(6):568-621 [17623612.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Sep;92(9):3466-9 [17579194.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2134-42 [17019736.001]
  • (PMID = 18402529.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD000642; United States / Intramural NIH HHS / / Z99 HD999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 67
  • [Other-IDs] NLM/ NIHMS101681; NLM/ PMC2670186
  •  go-up   go-down


2. Hwang SJ, Tsai SJ, Chen IJ, Hsu FC, Li C, Kao KP: Choking incidents among psychiatric inpatients: a retrospective study in Chutung Veterans General Hospital. J Chin Med Assoc; 2010 Aug;73(8):419-24
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All choking incidents recorded over 3 years in 3 psychiatric wards of Chutung Veterans General Hospital (total of 210 beds) were retrospectively analyzed for demographic variables, psychiatric and medical diagnoses, and drug therapy at the time of the incidents.
  • Men were 3 times more likely to experience choking incidents than women, and the mean age of choking patients was higher than that of all patients (59.7 vs. 44.4 years).
  • A high re-choking rate of up to 40.0% was noted, and patients with organic mental disorder had 3.4 times the choking incidence of all patients.
  • Up to 62.5% of the choking accidents occurred at breakfast, and mantou (a type of steamed bun) was the most common food (9/16) that resulted in the accidents.
  • We found that older age, male sex, higher dosage of hypnotics, previous choking attacks, organic mental disorder, poor self-care, breakfast time and mantou were possible risk factors associated with choking, in which older age, poor self-care, and higher dosage of hypnotics for fatal cases were statistically significant.

  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20728853.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


3. Bersot TP, Palaoğlu KE, Mahley RW: Managing dyslipidemia in Turkey: suggested guidelines for a population characterized by low levels of high density lipoprotein cholesterol. Anadolu Kardiyol Derg; 2002 Dec;2(4):315-22
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on data from the Turkish Society of Cardiology and others, it is established that Turks have a high prevalence of coronary heart disease (CHD).
  • The low HDL-C levels appear to be genetic in origin and are largely independent of high triglyceride levels (73% of Turkish men and 94% of women with HDL-C <40 mg/dl have triglyceride levels <150 mg/dl; only 15% of men and 3% of women with HDL-C <40 mg/dl have triglyceride levels >200 mg/dl).
  • Existing treatment guidelines focus on plasma LDL-C levels and fail to take into account the continuous increase in CHD risk that occurs as HDL-C levels decrease.
  • However, several studies show that patients with CHD or free of CHD but with multiple risk factors, who have low HDL-C and near optimal LDL-C, benefit very significantly from lipid-lowering therapy.
  • Many of these patients with low HDL-C levels do not qualify for drug therapy based on existing guidelines.
  • Therefore, we believe that unique guidelines must be developed to guide the treatment of low HDL-C Turkish patients.
  • We suggest that treatment based on both the LDL-C level and the total cholesterol/HDL-C (TC/HDL-C) ratio is the best way to address treatment of patients with low HDL-C levels.
  • The most effective drug treatment available presently in Turkey relies on lowering LDL-C levels to optimize the TC/HDL-C ratio.
  • [MeSH-major] Cholesterol, HDL / blood. Coronary Disease / prevention & control. Hyperlipidemias / prevention & control. Practice Guidelines as Topic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12460830.001).
  • [ISSN] 1302-8723
  • [Journal-full-title] Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
  • [ISO-abbreviation] Anadolu Kardiyol Derg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Cholesterol, HDL; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  • [Number-of-references] 52
  •  go-up   go-down


Advertisement
4. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS: Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther; 2007 Mar;81(3):346-53
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist. dl-MPH HCl (0.3 mg/kg) was administered orally 30 min before ethanol, 30 min after ethanol (0.6 gm/kg), or without ethanol, in a randomized, normal subject three-way crossover study of 10 men and 10 women.
  • Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).
  • Women reported a significantly greater stimulant effect than men when questioned "Do you feel any drug effect?
  • " (P<0.05), in spite of lower mean plasma d-MPH area under the response-time curves in women.
  • Ethanol elevates plasma d-MPH C(max) and area under the concentration-time curve by approximately 40% and 25%, respectively.
  • If the poor metabolizer of MPH proves to be a distinct phenotype, determining the genetic mechanism may be of value for individualizing drug therapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Metab Dispos. 2000 Jun;28(6):620-4 [10820132.001]
  • [Cites] Expert Opin Drug Deliv. 2005 Jan;2(1):121-43 [16296740.001]
  • [Cites] Pharm Res. 2000 Apr;17(4):381-4 [10870979.001]
  • [Cites] Drug Alcohol Depend. 2002 Jul 1;67(2):149-56 [12095664.001]
  • [Cites] J Clin Psychopharmacol. 2002 Dec;22(6):633-4 [12454570.001]
  • [Cites] J Atten Disord. 2002;6 Suppl 1:S101-7 [12685524.001]
  • [Cites] Pharmacotherapy. 2003 May;23(5):609-17 [12741435.001]
  • [Cites] Pharmacotherapy. 2003 Oct;23(10):1281-99 [14594346.001]
  • [Cites] Am J Psychiatry. 2003 Nov;160(11):1909-18 [14594733.001]
  • [Cites] Am J Psychiatry. 1972 Sep;129(3):342-5 [5053717.001]
  • [Cites] J Chromatogr. 1985 Oct 11;343(2):329-38 [4066874.001]
  • [Cites] J Pharmacol Exp Ther. 1987 Apr;241(1):152-8 [3572779.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1991 Sep;30(5):773-5 [1938793.001]
  • [Cites] Life Sci. 1992;51(8):553-63 [1640806.001]
  • [Cites] Life Sci. 1994;55(7):541-50 [8041232.001]
  • [Cites] Am J Psychiatry. 1995 Nov;152(11):1652-8 [7485630.001]
  • [Cites] Psychopharmacology (Berl). 1996 Jan;123(1):26-33 [8741951.001]
  • [Cites] Ther Drug Monit. 1996 Aug;18(4):460-4 [8857569.001]
  • [Cites] Psychiatry Res. 1998 Mar 20;78(1-2):115-8 [9579707.001]
  • [Cites] Exp Clin Psychopharmacol. 1998 Nov;6(4):367-74 [9861551.001]
  • [Cites] J Clin Psychopharmacol. 1999 Aug;19(4):362-6 [10440465.001]
  • [Cites] Psychiatr Serv. 1999 Aug;50(8):1001-3 [10445644.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2876-81 [15828826.001]
  • [Cites] Subst Use Misuse. 2005;40(4):511-28 [15830733.001]
  • [Cites] J Clin Psychiatry. 2000 Apr;61(4):244-51 [10830144.001]
  • (PMID = 17339864.001).
  • [ISSN] 0009-9236
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR01070; United States / NIAAA NIH HHS / AA / R01 AA016707; United States / NIDA NIH HHS / DA / R01 DA-15797; United States / NIAAA NIH HHS / AA / R01AA016707; United States / NIDA NIH HHS / DA / R01 DA015797; United States / NCRR NIH HHS / RR / M01 RR001070
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate; 3K9958V90M / Ethanol; 57413-43-1 / ethylphenidate
  • [Other-IDs] NLM/ NIHMS238458; NLM/ PMC3188424
  •  go-up   go-down


5. Vidal M, Wells S, Ryan A, Cagan R: ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res; 2005 May 1;65(9):3538-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
  • Patients with hereditary medullary thyroid carcinoma (MTC) associated with multiple endocrine neoplasia (MEN) types 2A and 2B and familial MTC (FMTC) have mutations in the RET proto-oncogene.
  • The RET point mutations associated with MEN2A, MEN2B, or FMTC, or the chromosomal breakpoints and translocations associated with PTC, typically activate the RET receptor tyrosine kinase (RTK).
  • RET kinase inhibitors are likely to be beneficial for patients with hereditary MTC, where currently there is no effective chemotherapy or radiation therapy.
  • We have developed a Drosophila model for MEN2A and MEN2B diseases by targeting oncogenic forms of RET to the developing Drosophila eye.
  • Our results support the view that targeting chemical kinase inhibitors such as ZD6474 to tissues with oncogenic forms of RET is a useful treatment strategy for RET-dependent carcinomas.
  • [MeSH-major] Carcinoma, Papillary / drug therapy. Drosophila Proteins / antagonists & inhibitors. Multiple Endocrine Neoplasia Type 2a / drug therapy. Multiple Endocrine Neoplasia Type 2b / drug therapy. Piperidines / pharmacology. Quinazolines / pharmacology. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Drosophila. Eye Abnormalities / genetics. Protein Isoforms. Proto-Oncogene Proteins c-ret. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. raf Kinases / antagonists & inhibitors. raf Kinases / genetics. raf Kinases / metabolism. ras Proteins / antagonists & inhibitors. ras Proteins / genetics. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • FlyBase. FlyBase .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867345.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA084309
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Protein Isoforms; 0 / Quinazolines; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Ret oncogene protein, Drosophila; EC 2.7.11.1 / raf Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


6. Chartier-Kastler E, Azouvi P, Yakovleff A, Bussel B, Richard F, Denys P: Intrathecal catheter with subcutaneous port for clonidine test bolus injection. A new route and type of treatment for detrusor hyperreflexia in spinal cord-injured patients. Eur Urol; 2000 Jan;37(1):14-7
Hazardous Substances Data Bank. CLONIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal catheter with subcutaneous port for clonidine test bolus injection. A new route and type of treatment for detrusor hyperreflexia in spinal cord-injured patients.
  • METHODS: According to approval of the local ethics committee, 9 consecutive SCI patients (6 men, 3 women) had catheter and port implantation between January 1998 and May 1999.
  • All did not respond to systemic drug therapy in combination to self-clean intermittent catheterisation (SCIC).
  • After clonidine bolus injection test and validation, 6 patients decided to have permanent pump implantation, 2 chose other therapies and one did not tolerate clonidine intrathecal injections for blood arterial pressure side effects.
  • CONCLUSIONS: Intrathecal clonidine may represent a useful conservative treatment of both severe bladder hyperreflexia and spinal spasticity.
  • Its short-term effects can be individually evaluated through bolus injection in subcutaneous port before definitive pump implantation.
  • [MeSH-major] Catheters, Indwelling. Clonidine / administration & dosage. Spinal Cord Injuries / complications. Sympatholytics / administration & dosage. Urinary Bladder Diseases / drug therapy. Urinary Bladder Diseases / etiology
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Male. Middle Aged. Muscle, Smooth / drug effects. Muscle, Smooth / physiopathology. Reflex, Abnormal / drug effects. Spine

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671778.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Sympatholytics; MN3L5RMN02 / Clonidine
  •  go-up   go-down


7. Gerstenfeld EP, Callans DJ, Sauer W, Jacobson J, Marchlinski FE: Reentrant and nonreentrant focal left atrial tachycardias occur after pulmonary vein isolation. Heart Rhythm; 2005 Nov;2(11):1195-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Both focal and macroreentrant atrial tachycardia (ATs) can occur after pulmonary vein (PV) isolation for treatment of atrial fibrillation (AF).
  • We report the response to pacing and pharmacologic maneuvers performed in patients with stable focal ATs after segmental PV isolation.
  • METHODS: Patients with persistent left AT after cessation of antiarrhythmic drug therapy presented for mapping and ablation.
  • Entrainment was performed from multiple right and left atrial sites.
  • RESULTS: Five patients (3 men and 2 women; age 65 +/- 10 years) had focal left AT that persisted in response to pacing maneuvers.
  • Tachycardias were entrained from multiple left atrial sites.
  • Recordings from the ablation catheter at the critical isthmus typically demonstrated mid-diastolic or long fractionated potentials.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253909.001).
  • [ISSN] 1547-5271
  • [Journal-full-title] Heart rhythm
  • [ISO-abbreviation] Heart Rhythm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Richter WO, Jahn P, Jung N, Nielebock E, Tachezy H: Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience. Ther Apher; 2001 Oct;5(5):335-9
MedlinePlus Health Information. consumer health - Diabetic Foot.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience.
  • Adsorbers containing 135 ml of coupled sepharose CL-4B were used to eliminate fibrinogen from the plasma of 7 men and 3 women (48-75 years old).
  • Nine patients suffered from diabetes mellitus, 1 patient from peripheral arterial occlusive disease, and 5 patients were on regular hemodialysis.
  • Treatments were scheduled on Days 1, 2, 4, 6, 8, 10, 13, 16, 19, 22, 25, and 28.
  • One hundred forty-four treatments with fibrinogen adsorption were performed.
  • No clinical side effects due to the fibrinogen adsorption procedure were observed.
  • In these 10 patients, fibrinogen concentration before the first treatment was 473.7 +/- 183.7 mg/dl.
  • In the first treatment session, fibrinogen concentration was lowered to 241.4 +/- 125.8 mg/dl by treating 4,270 +/- 1,180 ml of plasma.
  • In the following 134 treatments, the pretreatment concentration of fibrinogen was 262.6 +/- 83.4 mg/dl, and the posttreatment concentration was 120.6 +/- 37.2 mg/dl.
  • The mean amount of plasma treated was 3,737 +/- 1,643 ml, and the mean duration of a treatment session (except first treatment) was 143.7 +/- 63.1 min.
  • During the treatment period of 28 days, wound healing was observed in 9 of the 10 patients.
  • In conclusion, affinity chromatography using the pentapeptide gly-pro-arg-pro-lys is an effective, selective, and safe procedure to lower fibrinogen concentration in plasma.
  • It could be a therapeutic option in severe blood vessel disease in which drug therapy is not sufficient and invasive procedures such as bypass or angioplasty cannot be applied.
  • [MeSH-major] Arterial Occlusive Diseases / therapy. Blood Component Removal / methods. Diabetic Foot / therapy. Fibrinogen / therapeutic use
  • [MeSH-minor] Adsorption. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11778917.001).
  • [ISSN] 1091-6660
  • [Journal-full-title] Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis
  • [ISO-abbreviation] Ther Apher
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-32-5 / Fibrinogen
  •  go-up   go-down


9. Chamberlain MC, Raizer J: Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol; 2009 Jun;93(2):229-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
  • OBJECTIVE: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML).
  • BACKGROUND: Alkylator-based chemotherapy is recognized to be leukemogenic; however, it is infrequently described as a delayed consequence of anti-glioma treatment.
  • METHODS: Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients).
  • RESULTS: Exposure to alkylator-based chemotherapy ranged from 8 to 30 months (median 24).
  • The diagnosis of tMDS was determined by bone marrow biopsy in 7 patients.
  • Seven patients showed chromosomal abnormalities consistent with chemotherapy induced MDS.
  • Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 to 31 months (median 24 months).
  • CONCLUSIONS: Although rare, induction of tMDS/AML following extended use of alkylator-based chemotherapy may become more relevant with the evolving practice to treat gliomas for protracted periods.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Glioma / drug therapy. Myelodysplastic Syndromes / chemically induced
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nitrosourea Compounds / therapeutic use. Reoperation / statistics & numerical data. Survival Analysis. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] J Neurooncol. 2001 May;53(1):55-9 [11678432.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):315-8 [15735923.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] N Engl J Med. 1985 Aug 29;313(9):579 [3894973.001]
  • [Cites] Neurology. 2001 Jan 9;56(1):118-20 [11148250.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] Oncology. 2002;63(1):38-41 [12187069.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):39-46 [9874184.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Apr;42(4):170-4 [12013670.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):280-3 [16728498.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34 [10866347.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 19099199.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Nitrosourea Compounds; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


10. Simpson ND, Simpson PW, Ahmed AM, Nguyen MH, Garcia G, Keeffe EB, Ahmed A: Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. J Clin Gastroenterol; 2003 Jul;37(1):68-71
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
  • The results of lamivudine therapy in 4 patients with chemotherapy-induced hepatitis B virus (HBV) reactivation are reported.
  • Cancer chemotherapy-induced reactivation is a known complication in patients with chronic HBV infection or history of HBV infection with recovery.
  • The 4 patients treated with lamivudine included 1 woman with breast cancer and 3 men with non-Hodgkin lymphoma, ranging from 41 to 63 years of age.
  • All 4 patients were undergoing standard, multi-agent chemotherapy when they presented with HBV reactivation manifested by sudden onset of fatigue, jaundice, and HBV serology consistent with active HBV infection (detectable serum HBV DNA) in the absence of other known causes of acute hepatitis.
  • Lamivudine therapy (100 mg/d in 3 patients and 150 mg/d in 1 patient) was initiated from 1 to 18 days following the diagnosis of HBV reactivation.
  • All 4 patients showed rapid decrease in aminotransferase levels within 2 weeks after initiating lamivudine therapy.
  • The remaining 2 patients had suppression of HBV DNA to undetectable levels after 1 and 4 months of treatment and had biochemical and clinical improvement.
  • The 2 patients who died received lamivudine therapy for 8 days and for 3 weeks.
  • There have been no randomized clinical trials to study the role of lamivudine for prophylaxis or treatment of HBV reactivation associated with chemotherapy.
  • However, based on our limited experience, lamivudine may be efficacious in suppressing potentially fatal HBV reactivation secondary to chemotherapy in patients with chronic HBV infection or prior infection with recovery.
  • Patients who undergo chemotherapy should be screened for the presence of markers of chronic hepatitis B infection or previous HBV infection.
  • We recommend that patients with chronic HBV infection (positive HBV DNA and/or positive HBsAg) or history of HBV infection with recovery (positive hepatitis B core antibody with or without HBsAb) be considered for prophylactic lamivudine use to prevent chemotherapy-induced HBV reactivation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hepatitis B / prevention & control. Hepatitis B virus / growth & development. Lamivudine / therapeutic use. Reverse Transcriptase Inhibitors / therapeutic use. Virus Activation / drug effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12811213.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Lee SM, Kim SH, Lee JM, Im SA, Bang YJ, Kim WH, Kim MA, Yang HK, Lee HJ, Kang WJ, Han JK, Choi BI: Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdom Imaging; 2009 Jul;34(4):430-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer.
  • BACKGROUND: To investigate the utility of CT volumetry for primary gastric lesions in the prediction of pathologic response to neoadjuvant chemotherapy in patients with resectable advanced gastric cancer (AGC).
  • MATERIALS AND METHODS: Thirty-three consecutive patients with resectable AGC stage >or=T2 and N1), who had been treated with neoadjuvant chemotherapy and radical gastric resection, were prospectively enrolled in this study.
  • There were 30 men and 3 women with a mean age of 53.8 years.
  • Contrast-enhanced CT was obtained after gastric distention with air before and after chemotherapy using a MDCT scanner.
  • Pre- and post-chemotherapy thickness or short diameter and volume of the primary gastric tumor and largest lymph node (LN), were measured using a dedicated 3D software by two radiologists in consensus.
  • PET/CT was also performed and the peak standardized uptake value (SUV) of primary gastric tumor and largest LN before and after chemotherapy was measured.
  • CONCLUSION: CT volumetry for primary gastric tumor may be the most accurate tool in the prediction of pathologic response following neoadjuvant chemotherapy in patients with resectable AGC.
  • [MeSH-major] Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Gastrectomy / methods. Humans. Imaging, Three-Dimensional. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. ROC Curve. Radiographic Image Interpretation, Computer-Assisted. Sensitivity and Specificity. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546037.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


12. Chamberlain MC, Raizer J: Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia. J Clin Oncol; 2009 May 20;27(15_suppl):e13030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia.
  • : e13030 Background: Alkylator-based chemotherapy is recognized to be leukemogenic, however, it is infrequently described as a delayed consequence of anti-glioma treatment.
  • OBJECTIVE: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML).
  • METHODS: Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients).
  • RESULTS: Exposure to alkylator-based chemotherapy ranged from 8 months to 30 months (median 24).
  • The diagnosis of tMDS was determined by bone marrow biopsy in seven patients.
  • Seven patients showed chromosomal abnormalities consistent with chemotherapy induced MDS.
  • Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 months to 31 months (median 24 months).
  • CONCLUSIONS: Although rare, induction of tMDS/AML following extended use of alkylator-based chemotherapy may become more relevant with the evolving practice to treat gliomas for protracted periods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Fassas A, Fox M, Calandra G, Tricot G: Successful mobilization of peripheral blood stem cells (PBSCs) with AMD3100 in patients failing to collect with hematopoietic growth factors (HGF) and/or chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):6643

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful mobilization of peripheral blood stem cells (PBSCs) with AMD3100 in patients failing to collect with hematopoietic growth factors (HGF) and/or chemotherapy.
  • : 6643 Background: Poor mobilization of PBSCs compromises the application of effective high-dose treatment (HDT) in multiple myeloma (MM).
  • METHODS: Ten MM pts (3 men, 7 women) with a median age of 60 (range: 52-70) years who had failed to mobilize ≥ 5 million CD34 cells/kg PBSCs, received a daily dose of AMD3100 (240 μg/Kg) approximately 10 hours prior to each apheresis, for up to 7 days.
  • Eight pts had <12 months of preceding conventional chemotherapy, and one received HDTx2 > 4 years earlier.
  • Prior to AMD3100 administration, 14 attempts to collect PBSCs were performed following chemotherapy and HGF (n: 11) or HGF alone (n: 3) with a median of 0.19x10<sup>6</sup> CD34<sup>+</sup>/Kg (range: 0-2.94x10<sup>6</sup>) collected per attempt.
  • However, poor mobilization with chemotherapy and/or HGF also appears to predict for poor, although seemingly better, collection with AMD3100.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Spiliotis J, Tentes AA, Vaxevanidou A, Korakianitis OS, Rogdakis A, Mirelis CG, Datsis AC, Kekelos S: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece. J BUON; 2008 Apr-Jun;13(2):205-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece.
  • PURPOSE: To report our preliminary experience in the combined treatment of peritoneal carcinomatosis (PC) using cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).
  • RESULTS: Twenty-four patients (3 men and 21 women, mean age 60 years) were treated.
  • The mean duration of the procedure was 7.83 h (range 5 -12.30).
  • CONCLUSION: Our preliminary data suggest that the combined treatment of cytoreduction plus HIPEC for PC is associated with acceptable mortality and morbidity and offers an improved survival in these patients.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / economics. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Colonic Neoplasms / drug therapy. Colonic Neoplasms / economics. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonic Neoplasms / therapy. Female. Humans. Infusions, Parenteral. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / economics. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovarian Neoplasms / therapy. Prognosis. Prospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / economics. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Stomach Neoplasms / therapy. Survival Rate. Treatment Outcome. Uterine Neoplasms / drug therapy. Uterine Neoplasms / economics. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery. Uterine Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555466.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  •  go-up   go-down


15. Hamada H, Irifune K, Ito R, Sakai K, Kadowaki T, Katayama H, Abe M, Shiode M, Nishimura K, Higaki J: Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer. Gan To Kagaku Ryoho; 2007 Aug;34(8):1235-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
  • This pilot study evaluated the efficacy and toxicity of docetaxel and cisplatin as second-line chemotherapy for patients with advanced NSCLC.
  • PATIENTS AND METHODS: Eleven patients with advanced NSCLC who had no response to platinum-based treatment or had recurrence after a partial response were enrolled (2 stage III B, 9 stage IV; 8 men, 3 women).
  • Four weeks or more after the end of previous therapy, all 11 patients received docetaxel 60 mg/m2 and cisplatin 80 mg/m2 on day 1 every four weeks.
  • RESULTS: Two patients (18.2%) achieved a partial response,five (45.4%) patients had stable disease, and four (36.4%) patients showed progressive disease after initiation of second-line therapy.
  • Median time to disease progression was 101 days, and the one-year survival rate was 36.4%.
  • CONCLUSIONS: The regimen of docetaxel and cisplatin has reasonable efficacy with moderate toxicity as second-line chemotherapy for patients with previously treated, advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neutropenia / chemically induced. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687204.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Tanji N, Fukumoto T, Miura N, Yanagihara Y, Azuma K, Sasaki T, Nishida T, Kikugawa T, Shimamoto K, Aoki K, Yokoyama M: Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over. Anticancer Res; 2010 Sep;30(9):3839-43
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over.
  • BACKGROUND: This retrospective study aimed to determine the efficacy and toxicity of a combined chemotherapeutic regimen of gemcitabine and cisplatin (GC) for the treatment of metastatic urothelial carcinomas (UCs) in patients 80 years of age and over.
  • The patient cohort consisted of 9 men and 3 women, with a median age of 83 (range 80-84) years.
  • The median time to progression was 6 months, and the median overall survival was 14 months.
  • CONCLUSION: GC appears to be an effective and well-tolerated regimen for the treatment of metastatic UCs in very old patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944180.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Fukushima T, Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Soma G: Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas. Anticancer Res; 2003 Nov-Dec;23(6a):4473-81
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
  • BACKGROUND: This study assessed the safety, tolerance and preliminary efficacy of a combination chemotherapy regimen consisting of ranimustine (MCNU) and recombinant human mutant tumor necrosis factor-alpha (TNF-SAM2) for patients with newly diagnosed supratentorial malignant astrocytomas.
  • MATERIALS AND METHODS: The initial regimens were prescribed as adjuvant therapy in conjunction with radiotherapy following standard surgical treatment.
  • Ranimustine (MCNU) was administered intravenously at 100 mg/m2 on Day 1, i.e., at the onset of radiation therapy, and was followed by 80 x 10(4) U/m2 TNF-SAM2 intravenously from Day 3.
  • TNF-SAM2 was prescribed weekly for up to 5 injections during the postoperative period concurrent with radiation therapy.
  • The primary end-points were safety and tolerability and the secondary end-point was overall survival.
  • RESULTS: Twenty-six consecutive eligible patients, including 5 with anaplastic astrocytoma (3 men and 2 women) and 21 with glioblastoma (13 men and 8 women), were treated.
  • All of the 3 evaluable patients with anaplastic astrocytoma partially responded to treatment (PR), with a time to tumor progression (TTP) of 107 weeks and an estimated median survival time of 330 weeks.
  • Of the 15 evaluable patients with glioblastoma, 8 (53.3%) showed no change in response to the treatment (NC), while 7 (46.7%) had progressive disease (PD), with a time to tumor progression (TTP) of 36 weeks and an estimated median survival time of 69 weeks.
  • Although this regimen appeared to be safe, there was no improvement in response or survival time compared with a historical control of patients who received chemotherapy with MCNU alone in conjunction with radiotherapy for glioblastoma.
  • CONCLUSION: These results suggest that combined chemotherapy with mutant TNF-alpha (TNF-SAM2) in this patient population seems to be safe and tolerable and may benefit those with anaplastic astrocytoma.
  • These intriguing clinical observations warrant further evaluation to determine whether this approach can provide therapeutic benefits and improve survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Nitrosourea Compounds / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Immunotherapy. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666736.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / TNF-SAM2; 0 / Tumor Necrosis Factor-alpha; RYH2T97J77 / ranimustine
  •  go-up   go-down


18. Ciftci AO, Tanyel FC, Senocak ME, Büyükpamukçu N: Pheochromocytoma in children. J Pediatr Surg; 2001 Mar;36(3):447-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Information recorded for each patient included age, sex, past medical and family history, clinical characteristics, diagnostic methods, treatment, pathologic findings, and outcome.
  • Most of the tumors were right sided (n = 6) and bilateral (n = 6).
  • Sporadic cases of PHEO accounted for 14 patients (88%), whereas 2 children had von Hippel-Lindau (VHL) disease and multiple endocrine neoplasia type 2b (MEN2b).
  • The diagnosis of PHEO was made by laboratory and radiologic studies.
  • Preoperative medical therapy was done in all patients.
  • Laparotomy confirmed that 11 patients had localized, 4 patients had regional, and 1 patient had metastatic disease.
  • The localized tumors were excised totally by bilateral (n = 4) and unilateral (n = 6) adrenalectomy.
  • Surgical procedures performed for regional disease were total excision (n = 2), incisional biopsy (n = 1) and partial excision (n = 1).
  • Incisional biopsy could be taken only from a patient with metastatic disease at presentation.
  • Two patients with localized disease and 2 patients with regional disease had benign recurrences in right (n = 2) and left (n = 2) adrenal glands within 3 to 7 years after operation.
  • Total excision of the recurrent tumors was done in all patients.
  • Pathologic examination found apparently malignant features in 3 patients who presented with regional (n = 2) or metastatic (n = 1) disease and underwent incisional biopsy (n = 2) or partial excision (n = 1).
  • Pathologic features suggestive of malignancy were noted in 4 patients presenting with regional (n = 2) and localized disease (n = 2).
  • Adjuvant chemotherapy was commenced postoperatively in all patients with malignant and suggestive of malignant pathologic features.
  • One patient with VHL disease died of astrositoma 5 years after her recurrent PHEO was excised.
  • Of the 3 patients with malignant disease, 2 patients in whom only incisional biopsies were done had distant metastases and died of disease within 2 years.
  • Another patient with malignancy who had MEN2b was lost to follow-up.
  • CONCLUSIONS: Early diagnosis and total excision are the most important aspects of accurate treatment for childhood PHEO.
  • Pre- intra- and postoperative medical management is as important as the surgical procedure.
  • Our surgical treatment policy is mainly minimizing the risk of recurrence while preserving adequately functioning adrenal medullar tissue.
  • Incomplete excision and advanced-stage disease are the major determinants of poor outcome.
  • Because of the steadily increasing incidence of precancerous genetic syndromes related to adrenal glands and poor prognosis of advanced-stage PHEO, childhood cases of hypertensive disorders should receive a detailed and vigorous diagnostic evaluation and appropriate treatment as given to adults.
  • [MeSH-major] Adrenal Gland Neoplasms. Pheochromocytoma
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Female. Humans. Hypertension / etiology. Male. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Risk Factors. Treatment Outcome. Turkey


19. Gorla L, Mondellini P, Cuccuru G, Miccichè F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C, Bongarzone I: Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Mol Carcinog; 2009 Mar;48(3):220-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proteomics may help to elucidate differential signaling networks underlying the effects of compounds and to identify new therapeutic targets.
  • Using a proteomic-multiplexed analysis of the phosphotyrosine signaling together with antibody-based validation techniques, we identified several candidate molecules for RET (rearranged during transfection) tyrosine kinase receptor carrying mutations responsible for the multiple endocrine neoplasia type 2A and 2B (MEN2A and MEN2B) syndromes in two human medullary thyroid carcinoma (MTC) cell lines, TT and MZ-CRC-1, which express the RET-MEN2A and RET-MEN2B oncoproteins, respectively.
  • We detected 23 and 18 affinity-purified phosphotyrosine proteins in untreated TT and MZ-CRC-1 cells, respectively, most of which were shared and sensitive to RPI-1 treatment.
  • However, our data clearly point to specific signaling features of the RET-MEN2A and RET-MEN2B oncogenic pathways.
  • Moreover, the detection of high-level expression of minimally phosphorylated epidermal growth factor receptor (EGFR) in both TT and MZ-CRC-1 cells, together with our data on the effects of EGF stimulation on the proteomic profiles and the response to Gefitinib treatment, suggest the relevance of EGFR signaling in these cell lines, especially since analysis of 14 archival MTC specimens revealed EGFR mRNA expression in all samples.
  • Together, our data suggest that RET/EGFR multi-target inhibitors might be beneficial for therapy of MTC.
  • [MeSH-major] Germ-Line Mutation / genetics. Oncogene Proteins / metabolism. Proteomics. Proto-Oncogene Proteins c-ret / genetics. Proto-Oncogene Proteins c-ret / metabolism. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / genetics. Carcinoma, Medullary / metabolism. Epidermal Growth Factor / pharmacology. Female. Humans. Mice. Mice, Nude. Multiple Endocrine Neoplasia Type 2a / drug therapy. Multiple Endocrine Neoplasia Type 2a / genetics. Multiple Endocrine Neoplasia Type 2a / metabolism. Multiple Endocrine Neoplasia Type 2b / drug therapy. Multiple Endocrine Neoplasia Type 2b / genetics. Multiple Endocrine Neoplasia Type 2b / metabolism. Phosphorylation / drug effects. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Signal Transduction. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18756447.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oncogene Proteins; 0 / Quinazolines; 42HK56048U / Tyrosine; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


20. Quayle FJ, Moley JF: Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol; 2005 Mar 1;89(3):122-9
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
  • First, MTC may be sporadic (75% of cases), or may occur as a manifestation of the hereditary syndrome Multiple Endocrine Neoplasia type 2 (MEN 2) (25% of cases).
  • Finally, unlike differentiated thyroid cancer, there is no known effective systemic therapy for MTC.
  • MTC cells do not concentrate radioactive iodine, and MTC does not respond well to external beam radiation or conventional cytotoxic chemotherapy.
  • [MeSH-major] Carcinoma, Medullary. Multiple Endocrine Neoplasia Type 2a. Multiple Endocrine Neoplasia Type 2b. Thyroid Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcitonin / blood. Combined Modality Therapy. Dacarbazine / administration & dosage. Endocrine Surgical Procedures / methods. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Mutation. Parathyroidectomy. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-ret. Receptor Protein-Tyrosine Kinases / genetics. Thyroidectomy. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15719378.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 7GR28W0FJI / Dacarbazine; 9007-12-9 / Calcitonin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; U3P01618RT / Fluorouracil
  • [Number-of-references] 56
  •  go-up   go-down


21. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D: Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J Endocrinol Invest; 2007 Nov;30(10):RC31-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is no effective treatment for recurrent or metastatic medullary thyroid carcinoma (MTC), a tumor arising from thyroid C-cells commonly presenting an inherited or acquired RET mutation.
  • In TT cells [carrying the multiple endocrine neoplasia (MEN)2A Ret mutation Cys 634Trp] and MZ-CRC-1 cells (carrying the MEN2B RET mutation Met891Thr), one of these compounds, namely Si 34, determined a significant growth inhibitory effect (approximately 90% vs control for TT, 80% vs control for MZ-CRC-1) mainly due to enhanced cell mortality after a 6-day incubation.
  • These results, when confirmed in other in vivo preclinical models, suggest that this novel tyrosine kinase inhibitor may be useful for the treatment of MTC.
  • [MeSH-major] Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / pathology. Pyrazoles / pharmacology. Pyrimidines / pharmacology. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / pathology
  • [MeSH-minor] Apoptosis / drug effects. Cell Division / drug effects. Cell Line, Tumor. Humans. Multiple Endocrine Neoplasia Type 1 / drug therapy. Multiple Endocrine Neoplasia Type 1 / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Poly(ADP-ribose) Polymerases / metabolism. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-ret / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 2004 Mar 25;47(7):1595-8 [15027847.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2234-43 [12727845.001]
  • [Cites] J Endocrinol Invest. 2005 Feb;28(2):137-44 [15887859.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3503-9 [15240638.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):564-74 [17019434.001]
  • [Cites] Bioorg Med Chem Lett. 2004 May 17;14(10):2511-7 [15109642.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1077-82 [11861385.001]
  • [Cites] Clin Lab Med. 2004 Mar;24(1):49-83 [15157557.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1120-6 [10070972.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1897-902 [12679489.001]
  • [Cites] BMC Cancer. 2004 Sep 13;4:63 [15363094.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Feb 27;207(3):1022-8 [7864888.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):299-310 [15355445.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Jan;2(1):42-52 [16932252.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5620-35 [11114743.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Apr;80(2):138-49 [7736432.001]
  • [Cites] Endocr Rev. 2006 Aug;27(5):535-60 [16849421.001]
  • (PMID = 18075281.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrazoles; 0 / Pyrimidines; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  •  go-up   go-down


22. Das T, Cagan R: Drosophila as a novel therapeutic discovery tool for thyroid cancer. Thyroid; 2010 Jul;20(7):689-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drosophila as a novel therapeutic discovery tool for thyroid cancer.
  • BACKGROUND: Multiple endocrine neoplasia type II (MEN2) is a rare but aggressive cancer for which no effective treatment currently exists.
  • A Drosophila model was developed to identify novel genetic modifier loci of oncogenic RET, as well as to provide a whole animal system to rapidly identify compounds that suppressed RET-dependent MEN2.
  • ZD6474 (Vandetanib), currently in phase III trials, suppressed tumorigenesis in MEN2 model flies, demonstrating for the first time the effectiveness of a Drosophila-based whole animal model for identifying therapeutically useful compounds.
  • SUMMARY: Clinical data suggest that drug mono-therapy for MEN2 and other cancers typically yield only moderate benefits as patients develop drug resistance and suffer from drug-induced pathway feedback.
  • Combinations of drugs that target different nodes of the oncogenic pathway are an effective way to prevent resistance as well as feedback.
  • Identifying the optimal drug-dose combinations for therapy poses a significant challenge in existing mouse models.
  • Fly models offer a means to quickly and effectively identify drug combinations that are well tolerated and potently suppress the MEN2 phenotype.
  • This approach may also identify differences in therapeutic responses between the two subtypes of MEN2--MEN2A and MEN2B--providing additional therapeutic insights.
  • CONCLUSIONS: Fly models have proven useful for identifying known drugs as well as novel compounds that, as single agents or in combinations, effectively suppress the MEN2 syndrome.
  • These findings validate the use of fly models for both drug discovery as well as identification of useful drug combinations.
  • In the future, rapid pairing of new genomic information with increasingly complex fly models will aid us in efforts to further tailor drug treatments toward personalized medicine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease Models, Animal. Drosophila / drug effects. Drosophila / genetics. Drug Discovery / methods. Thyroid Neoplasms / drug therapy. Thyroid Nodule / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / genetics. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / secondary. Humans. Multiple Endocrine Neoplasia Type 2a / drug therapy. Multiple Endocrine Neoplasia Type 2a / genetics. Multiple Endocrine Neoplasia Type 2a / metabolism. Multiple Endocrine Neoplasia Type 2b / drug therapy. Multiple Endocrine Neoplasia Type 2b / genetics. Multiple Endocrine Neoplasia Type 2b / metabolism. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / secondary. Precision Medicine / methods. Proto-Oncogene Proteins c-ret / genetics. Signal Transduction / drug effects


23. Jin Y, Murakumo Y, Ueno K, Hashimoto M, Watanabe T, Shimoyama Y, Ichihara M, Takahashi M: Identification of a mouse cytoskeleton-associated protein, CKAP2, with microtubule-stabilizing properties. Cancer Sci; 2004 Oct;95(10):815-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microtubule dynamics is an important factor in cell proliferation and one of the main targets of cancer chemotherapy.
  • Since microtubule-associated proteins (MAPs) are known to influence microtubule stability, study of MAPs may contribute both to knowledge of cancer cell biology and to the production of new anti-cancer drugs.
  • The level of expression of mouse CKAP2 (mCKAP2) was significantly higher in NIH3T3 cells expressing RET with a multiple endocrine neoplasia (MEN) 2A or MEN2B mutation than in parental NIH3T3 cells.
  • Furthermore, overexpression of mCKAP2 in cells appeared to stabilize microtubules against treatment with nocodazole, a microtubule-depolymerizing agent.
  • These findings suggest that CKAP2 is a new MAP with microtubule-stabilizing properties and may represent a new molecular target for cancer chemotherapy.
  • [MeSH-major] Microtubules / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15504249.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY692438
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CKAP2 protein, mouse; 0 / Cytoskeletal Proteins; 0 / Proto-Oncogene Proteins; 0 / Tubulin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Ret protein, mouse; SH1WY3R615 / Nocodazole
  •  go-up   go-down


24. Health Quality Ontario: Endovascular laser therapy for varicose veins: an evidence-based analysis. Ont Health Technol Assess Ser; 2010;10(6):1-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endovascular laser therapy for varicose veins: an evidence-based analysis.
  • OBJECTIVE: The objective of the MAS evidence review was to conduct a systematic review of the available evidence on the safety, effectiveness, durability and cost-effectiveness of endovascular laser therapy (ELT) for the treatment of primary symptomatic varicose veins (VV).
  • BACKGROUND: The Ontario Health Technology Advisory Committee (OHTAC) met on November 27, 2009 to review the safety, effectiveness, durability and cost-effectiveness of ELT for the treatment of primary VV based on an evidence-based review by the Medical Advisory Secretariat (MAS).
  • The end result is pooling of blood in the veins, increased venous pressure and subsequent vein enlargement.
  • Ulceration represents the disease end point for severe CVI.
  • Lower limb VV is a common disease affecting adults and estimated to be the seventh most common reason for physician referral in the US.
  • Globally, the prevalence of VV ranges from 5% to 15% among men and 3% to 29% among women varying by the age, gender and ethnicity of the study population, survey methods and disease definition and measurement.
  • The annual incidence of VV estimated from the Framingham Study was reported to be 2.6% among women and 1.9% among men and did not vary within the age range (40-89 years) studied.
  • Approximately 1% of the adult population has a stasis ulcer of venous origin at any one time with 4% at risk.
  • Stasis ulcers are often lengthy medical problems and can last for several years and, despite effective compression therapy and multilayer bandaging are associated with high recurrence rates.
  • Recent trials involving surgical treatment of superficial vein reflux have resulted in healing and significantly reduced recurrence rates.
  • ENDOVASCULAR LASER THERAPY FOR VV: ELT is an image-guided, minimally invasive treatment alternative to surgical stripping of superficial venous reflux.
  • Prior to ELT, colour-flow Doppler ultrasonography is used to confirm and map all areas of venous reflux to devise a safe and effective treatment plan.
  • The ELT procedure involves the introduction of a guide wire into the target vein under ultrasound guidance followed by the insertion of an introducer sheath through which an optical fibre carrying the laser energy is advanced.
  • A tumescent anesthetic solution is injected into the soft tissue surrounding the target vein along its entire length.
  • This serves to anaesthetize the vein so that the patient feels no discomfort during the procedure.
  • At the end of the procedure, homeostasis is then achieved by applying pressure to the entry point.
  • Adequate and proper compression stockings and bandages are applied after the procedure to reduce the risk of venous thromboembolism, and to reduce postoperative bruising and tenderness.
  • Patients are encouraged to walk immediately after the procedure and most patients return to work or usual activity within a few days.
  • Patients often have a second follow-up visit 1-3 months following ELT at which time clinical evaluation and ultrasound are repeated.
  • If required, sclerotherapy may be performed during the ELT procedure or at any follow-up visits.
  • REGULATORY STATUS: Endovascular laser for the treatment of VV was approved by Health Canada as a class 3 device in 2002.
  • The treatment has been an insured service in Saskatchewan since 2007 and is the only province to insure ELT.
  • Although the treatment is not an insured service in Ontario, it has been provided by various medical specialties since 2002 in over 20 private clinics.
  • Imaging defined treatment effectiveness of mean vein closure rates were reported to be greater than 90% (range 93%- 99%) at short term follow-up.
  • Recovery after treatment was significantly quicker after ELT (return to work median number of days, 4 vs. 17; p= .005).
  • Treatment effectiveness as measured by imaging vein absence or closure, symptom relief or quality of life similar in the two treatment groups and both treatments resulted in statistically significantly improvements in these outcomes.
  • Recurrence was low after both treatments at follow up but neovascularization (growth of new vessels, a key predictor of long term recurrence was significantly more common (18% vs. 1%; p = .001) after surgery.
  • Although patient satisfaction was reported to be high (>80%) with both treatments, patient preferences evaluated through recruitment process, physician reports and consumer groups were strongly in favour of ELT.
  • As clinical effectiveness of the two treatments was similar, a cost-analysis was performed to compare differences in resources and costs between the two procedures.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann R Coll Surg Engl. 2007 Mar;89(2):96-100 [17346396.001]
  • [Cites] Curr Treat Options Cardiovasc Med. 2007 Apr;9(2):115-26 [17484814.001]
  • [Cites] J Vasc Surg. 2007 Aug;46(2):308-15 [17600655.001]
  • [Cites] J Vasc Interv Radiol. 2007 Sep;18(9):1073-80 [17804767.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1243-9 [17903158.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2008 Jan;35(1):119-23 [17936037.001]
  • [Cites] J Vasc Surg. 2007 Dec;46(6):1242-7 [18155001.001]
  • [Cites] Vasc Endovascular Surg. 2008 Apr-May;42(2):141-9 [18238860.001]
  • [Cites] Dermatol Surg. 2008 Apr;34(4):517-24; discussion 524 [18248488.001]
  • [Cites] J Vasc Surg. 2008 Apr;47(4):822-9; discussion 829 [18295441.001]
  • [Cites] J Vasc Interv Radiol. 2008 Feb;19(2 Pt 1):211-5 [18341951.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2008 Jun;35(6):745-9 [18343168.001]
  • [Cites] Phlebology. 2008;23(1):2-9 [18361263.001]
  • [Cites] Phlebology. 2008;23(1):21-31 [18361266.001]
  • [Cites] Ann Vasc Surg. 2009 Jan-Feb;23(1):39-42 [18619773.001]
  • [Cites] Phlebology. 2008;23(4):172-7 [18663116.001]
  • [Cites] Ann Vasc Surg. 2009 Mar;23(2):207-11 [18684588.001]
  • [Cites] J Vasc Surg. 2008 Oct;48(4):947-52 [18692346.001]
  • [Cites] J Vasc Interv Radiol. 2008 Oct;19(10):1449-53 [18760628.001]
  • [Cites] Br J Surg. 2008 Oct;95(10):1232-8 [18763255.001]
  • [Cites] J Vasc Surg. 2008 Dec;48(6):1538-45 [18829223.001]
  • [Cites] J Am Acad Dermatol. 2009 Jan;60(1):110-9 [18835063.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Feb;37(2):239-45 [18993093.001]
  • [Cites] Int Angiol. 2008 Dec;27(6):475-81 [19078909.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Mar;37(3):357-63 [19111485.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Apr;37(4):486-91 [19119027.001]
  • [Cites] Phlebology. 2009 Feb;24(1):26-30 [19155338.001]
  • [Cites] Br J Surg. 2009 Apr;96(4):369-75 [19283745.001]
  • [Cites] Curr Treat Options Cardiovasc Med. 2009 Apr;11(2):91-103 [19289022.001]
  • [Cites] Phlebology. 2009;24 Suppl 1:3-12 [19307437.001]
  • [Cites] Phlebology. 2009;24 Suppl 1:34-41 [19307439.001]
  • [Cites] J Vasc Surg. 2009 Apr;49(4):973-979.e1 [19341887.001]
  • [Cites] Dermatol Surg. 2009 May;35(5):804-12 [19389098.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Aug;38(2):208-12 [19464201.001]
  • [Cites] Dermatol Surg. 2009 Aug;35(8):1206-14 [19469796.001]
  • [Cites] Phlebology. 2009 Jun;24(3):125-30 [19470864.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Aug;38(2):203-7 [19524460.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Aug;38(2):199-202 [19616756.001]
  • [Cites] Cardiovasc Intervent Radiol. 2009 Sep;32(5):988-91 [19536594.001]
  • [Cites] Singapore Med J. 2009 Jun;50(6):591-4 [19551312.001]
  • [Cites] Am J Prev Med. 1988 Mar-Apr;4(2):96-101 [3395496.001]
  • [Cites] Br J Surg. 1994 Feb;81(2):167-73 [8156326.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):318-26 [8176043.001]
  • [Cites] Qual Life Res. 1996 Apr;5(2):223-34 [8998491.001]
  • [Cites] BMJ. 1999 Feb 6;318(7180):353-6 [9933194.001]
  • [Cites] Ann Intern Med. 2001 Apr 17;134(8):663-94 [11304107.001]
  • [Cites] J Vasc Surg. 2001 Oct;34(4):641-8 [11668318.001]
  • [Cites] J Vasc Surg. 2003 Aug;38(2):224-8 [12891101.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Mar;27(3):269-74 [14760595.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1854-9 [15183623.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] Semin Vasc Surg. 2005 Mar;18(1):15-8 [15791548.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2006 Mar;31(3):288-99 [16230038.001]
  • [Cites] J Vasc Surg. 2006 Jan;43(1):81-87 [16414393.001]
  • [Cites] J Cosmet Laser Ther. 2007 Mar;9(1):9-13 [17457762.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2008 Jan;35(1):88-95 [17920307.001]
  • [Cites] J Vasc Surg. 2007 Dec;46 Suppl S:4S-24S [18068561.001]
  • [Cites] J Vasc Surg. 2007 Dec;46 Suppl S:54S-67S [18068562.001]
  • [Cites] Br J Surg. 2008 Mar;95(3):294-301 [18278775.001]
  • [Cites] J Cardiovasc Surg (Torino). 2008 Apr;49(2):213-33 [18431342.001]
  • [Cites] J Vasc Surg. 2008 Jul;48(1):173-8 [18440756.001]
  • [Cites] Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):126-36 [18537763.001]
  • [Cites] J Vasc Surg. 2008 Sep;48(3):675-9 [18586448.001]
  • [Cites] J Vasc Surg. 2008 Oct;48(4):940-6 [18639418.001]
  • [Cites] J Vasc Surg. 2008 Aug;48(2):400-5; discussion 405-6 [18644484.001]
  • [Cites] J Vasc Surg. 2009 Jan;49(1):230-9 [18692348.001]
  • [Cites] Phlebology. 2008;23(5):206-13 [18806202.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2008 Dec;36(6):713-8 [18848791.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2008 Dec;36(6):738-42 [18851921.001]
  • [Cites] Ann Vasc Surg. 2009 Mar;23(2):264-76 [19059756.001]
  • [Cites] Ann Vasc Surg. 2009 Mar;23(2):277-87 [19128927.001]
  • [Cites] Semin Cutan Med Surg. 2008 Dec;27(4):264-75 [19150298.001]
  • [Cites] Perspect Vasc Surg Endovasc Ther. 2009 Mar;21(1):21-6 [19190036.001]
  • [Cites] Phlebology. 2009;24 Suppl 1:50-61 [19307441.001]
  • [Cites] Phlebology. 2009;24 Suppl 1:62-72 [19307442.001]
  • [Cites] J Vasc Interv Radiol. 2009 Jun;20(6):752-9 [19395275.001]
  • [Cites] Perspect Vasc Surg Endovasc Ther. 2009 Jun;21(2):69-72 [19602507.001]
  • [Cites] Perspect Vasc Surg Endovasc Ther. 2009 Jun;21(2):94-104 [19640861.001]
  • [Cites] Perspect Vasc Surg Endovasc Ther. 2009 Jun;21(2):73-81 [19703822.001]
  • [Cites] Perspect Vasc Surg Endovasc Ther. 2009 Jun;21(2):91-3 [19767405.001]
  • [Cites] Phlebology. 2009 Aug;24(4):151-6 [19620697.001]
  • [Cites] Dermatol Surg. 1997 Jan;23(1):51-4 [9107295.001]
  • [Cites] Ann R Coll Surg Engl. 1997 Mar;79(2):105-10 [9135236.001]
  • [Cites] J Vasc Surg. 1999 Apr;29(4):589-92 [10194484.001]
  • [Cites] J Vasc Surg. 2000 Jun;31(6):1307-12 [10842165.001]
  • [Cites] Cardiovasc Surg. 2000 Jun;8(4):233-45 [10950599.001]
  • [Cites] J Vasc Surg. 2002 Aug;36(2):416-22 [12170230.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2003 Apr;25(4):313-8 [12651168.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2003 Apr;25(4):319-24 [12651169.001]
  • [Cites] J Vasc Surg. 2003 May;37(5):1047-53 [12756353.001]
  • [Cites] J Vasc Surg. 2003 Nov;38(5):935-43 [14603197.001]
  • [Cites] Tech Vasc Interv Radiol. 2003 Sep;6(3):111-5 [14614694.001]
  • [Cites] Tech Vasc Interv Radiol. 2003 Sep;6(3):116-20 [14614695.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Feb;27(2):113-20 [14718891.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):291-7 [15584055.001]
  • [Cites] J Vasc Surg. 2004 Dec;40(6):1248-52 [15622385.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2005 Jul;30(1):83-95 [15933989.001]
  • [Cites] Int Angiol. 2005 Sep;24(3):272-7 [16158038.001]
  • [Cites] Br J Surg. 2005 Oct;92(10):1189-94 [16175538.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2006 Jan;31(1):83-92 [16226898.001]
  • [Cites] Dermatol Surg. 2005 Dec;31(12):1685-94; discussion 1694 [16336888.001]
  • [Cites] Ann Vasc Surg. 2006 Jul;20(4):547-52 [16791452.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2007 May;33(5):614-8 [17227716.001]
  • [Cites] Adv Dermatol. 2006;22:139-56 [17249300.001]
  • [Cites] J Vasc Surg. 2007 Apr;45(4):795-801; discussion 801-3 [17306952.001]
  • (PMID = 23074409.001).
  • [ISSN] 1915-7398
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3377531
  •  go-up   go-down


25. Dayi SU, Kasikcioglu H, Uslu N, Tartan Z, Uyarel H, Terzi S, Hobikoglu G, Okmen E, Cam N: Influence of weight loss on myocardial performance index. Heart Vessels; 2006 Mar;21(2):84-8
Hazardous Substances Data Bank. ORLISTAT .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 18 obese patients (3 men, 15 women, mean age 49.6 +/- 5.5 years, body mass index [BMI] >30 kg/m(2)) were investigated in the study.
  • All patients were treated with a multidisciplinary approach consisting of a hypocaloric diet and orlistat therapy (120 mg three times daily), and all of them underwent two-dimensional and Doppler echocardiographic examination two times before starting the study and after a period of weight loss.
  • Using echo-Doppler methods, ejection fraction, peak velocities of early (E) and late (A) diastolic filling, the E/A ratio, deceleration time (DT), isovolumic contraction time (IVCT), isovolumic relaxation time, ejection time, and MPI were measured.
  • The MPI was obtained by subtraction ejection time from the interval between cessation and onset of the mitral flow.
  • Compared with baseline, after weight loss the E/A ratio of 1.01 +/- 0.22 before treatment increased to 1.17 +/- 0.26 (P = 0.012), left ventricular mass index decreased from 88 +/- 23 to 82 +/- 19 g/m(2) (P = 0.028), IVCT from 71 +/- 20 to 53 +/- 30 ms (P = 0.004), DT from 233.65 +/- 38.14 to 196.72 +/- 47.73 s (P = 0.004), and MPI from 0.63 +/- 0.13 to 0.50 +/- 0.13 (P = 0.0001).
  • [MeSH-minor] Anti-Obesity Agents / therapeutic use. Body Mass Index. Diet, Reducing. Echocardiography, Doppler. Female. Humans. Lactones / therapeutic use. Male. Middle Aged. Prognosis. Prospective Studies. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Echocardiogr. 1997 Mar;10 (2):169-78 [9083973.001]
  • [Cites] Jpn Circ J. 2001 Jul;65(7):637-42 [11446498.001]
  • [Cites] Am J Cardiol. 1999 Nov 1;84(9):1127-9, A11 [10569684.001]
  • [Cites] Diabetes Care. 2004 Jan;27(1):47-52 [14693965.001]
  • [Cites] Am J Cardiol. 1999 Mar 1;83(5):728-34 [10080427.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):694-9 [1514498.001]
  • [Cites] J Am Coll Cardiol. 1996 Sep;28(3):658-64 [8772753.001]
  • [Cites] Am J Cardiol. 1998 Nov 1;82(9):1071-6 [9817484.001]
  • [Cites] Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):325-34 [3975428.001]
  • [Cites] Eur Heart J. 2000 Jan;21(2):94-6 [10637079.001]
  • [Cites] J Am Coll Cardiol. 1998 Oct;32(4):865-75 [9768704.001]
  • [Cites] Circulation. 1957 Aug;16(2):179-87 [13447161.001]
  • [Cites] J Am Soc Echocardiogr. 2002 Sep;15(9):864-8 [12221401.001]
  • [Cites] J Cardiol. 1995 Dec;26(6):357-66 [8558414.001]
  • [Cites] Circulation. 1997 Nov 4;96(9):3248-50 [9386201.001]
  • [Cites] Am J Cardiol. 1991 Jul 1;68(1):95-8 [1829321.001]
  • [Cites] Heart. 2003 Oct;89(10):1152-6 [12975404.001]
  • [Cites] Obes Res. 2000 Jan;8(1):49-61 [10678259.001]
  • [Cites] Am J Cardiol. 2000 Jan 1;85(1):19-25 [11078230.001]
  • [Cites] Eur Heart J. 2000 Nov;21(22):1888-95 [11052862.001]
  • [Cites] N Engl J Med. 2002 Aug 1;347(5):305-13 [12151467.001]
  • [Cites] Eur Heart J. 2004 Dec;25(24):2220-5 [15589639.001]
  • [Cites] J Am Soc Echocardiogr. 2000 May;13(5):379-84 [10804435.001]
  • [Cites] Hellenic J Cardiol. 2005 Jan-Feb;46(1):52-8 [15807396.001]
  • [Cites] Heart Vessels. 2004 Mar;19(2):68-74 [15042390.001]
  • (PMID = 16550308.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Obesity Agents; 0 / Lactones; 95M8R751W8 / orlistat
  •  go-up   go-down


26. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA: Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol; 2005 Jun;173(6):1958-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We reviewed the records of 16 men who presented consecutively to our institution with genitourinary melanoma between 1962 and 2000.
  • In 7 patients with T1-2N0M0 disease there were no local recurrences after wide local excision (WLE) or partial penectomy at a median followup of 35 months.
  • Six of 7 men were rendered disease-free.
  • One patient died of melanoma that developed at a second primary site.
  • The 3 patients with T3 tumors who underwent partial (2) or radical (1) penectomy with or without BILND died of disease (2) or had progression (1).
  • In all patients with penile melanoma the 5-year actuarial disease specific and recurrence-free survival rates were 80% and 60%, respectively, at a median followup of 39 months (range 20 to 210).
  • Three of the 6 patients had palpable inguinal nodes, of whom 2 died after chemotherapy for unresectable disease and 1 died of other causes 51 months after negative BILND.
  • The 3 men with clinically negative groins who did not undergo prophylactic BILND had distant (1) or regional (2) metastases and died of disease.
  • In patients with scrotal melanoma the 5-year actuarial disease specific and recurrence-free survival rates were 33.3% and 33.3%, respectively, at a median followup of 36 months.
  • Patients showing clinically positive, proven metastasis died despite appropriate surgical procedures and multi-agent chemotherapy.
  • [MeSH-major] Genital Neoplasms, Male / surgery. Melanoma / surgery. Penile Neoplasms / surgery. Scrotum / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2006 Apr;175(4):1574-5; author reply 1575-6 [16516049.001]
  • (PMID = 15879790.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Puri AS, Monga R, Garg S, Sharma BC, Satapathy S, Sarin SK: Diaphragm disease of duodenum following long-term NSAIDs use: endoscopic management. Indian J Gastroenterol; 2004 Sep-Oct;23(5):189-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diaphragm disease of duodenum following long-term NSAIDs use: endoscopic management.
  • We report our experience with endoscopic management of 3 men (aged 62, 63 and 65 years) with duodenal diaphragm disease following NSAID use for 5-15 years.
  • [MeSH-minor] Aged. Diaphragm / pathology. Dose-Response Relationship, Drug. Follow-Up Studies. Humans. Long-Term Care. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Rheumatic Diseases / diagnosis. Rheumatic Diseases / drug therapy. Risk Assessment. Sampling Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15599008.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


28. Kuenzel HE, Murck H, Held K, Ziegenbein M, Steiger A: Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression. Pharmacopsychiatry; 2004 Sep;37(5):193-5
Hazardous Substances Data Bank. REBOXETINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The influence of reboxetine on the sleep-EEG of eight patients with depression HAMD (mean +/- SD) 19.7 +/- 1.5 (5 women, 3 men; age range 31 to 75 years) was investigated.
  • The first examination was performed before starting active medication.
  • RESULTS: Conventional sleep-EEG analysis showed a significant increase in intermittent wakefulness and sleep stage 2 and a decrease in sleep efficiency and REM time.
  • CONCLUSION: Our results indicate, that reboxetine induces sleep-EEG changes similar to those after selective serotonin reuptake inhibitors (SSRI's) by increasing intermittent wakefulness and decreasing REM time.
  • [MeSH-major] Adrenergic Uptake Inhibitors / pharmacology. Adrenergic Uptake Inhibitors / therapeutic use. Depressive Disorder, Major / drug therapy. Electroencephalography / drug effects. Fluoxetine / pharmacology. Fluoxetine / therapeutic use. Morpholines / adverse effects. Morpholines / therapeutic use. Serotonin Uptake Inhibitors / pharmacology. Serotonin Uptake Inhibitors / therapeutic use. Sleep Initiation and Maintenance Disorders / chemically induced. Sleep Stages / drug effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Wakefulness / drug effects

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Insomnia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15359374.001).
  • [ISSN] 0176-3679
  • [Journal-full-title] Pharmacopsychiatry
  • [ISO-abbreviation] Pharmacopsychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Morpholines; 0 / Serotonin Uptake Inhibitors; 01K63SUP8D / Fluoxetine; 947S0YZ36I / reboxetine
  •  go-up   go-down


29. Bänsch D, Oyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, Ernst S, Kuck KH: Successful catheter ablation of electrical storm after myocardial infarction. Circulation; 2003 Dec 16;108(24):3011-6
MedlinePlus Health Information. consumer health - Heart Attack.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We report on 4 patients (aged 57 to 77 years; 3 men) who developed drug-refractory, repetitive ventricular tachyarrhythmias after acute myocardial infarction (MI).
  • RF ablation of the triggering VPBs is feasible and can prevent drug-resistant electrical storm, even after acute MI.
  • Catheter ablation of the triggering VPBs may be used as a bailout therapy in these patients.
  • [MeSH-minor] Aged. Electrocardiography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14662718.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Shin TW, Wilson M, Wilson TW: Are hot tubs safe for people with treated hypertension? CMAJ; 2003 Dec 9;169(12):1265-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared symptoms, heart rate, and systolic and diastolic blood pressure in response to 10 minutes of hot-tub immersion in a group of patients with treated hypertension and in a control group normotensive subjects.
  • METHODS: We recruited 21 patients (18 men and 3 women aged 43-76 years) with stable, treated hypertension and 23 control subjects (14 men and 9 women aged 19-83 years) without hypertension.
  • Systolic and diastolic blood pressure and heart rate were measured at baseline, during immersion in a hot tub at 40 degrees C and for 10 minutes after immersion.
  • Diastolic blood pressure also fell, whereas heart rate was increased in both groups.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Hot Temperature / adverse effects. Hypertension / diagnosis. Hypertension / drug therapy. Immersion / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Pressure Determination. Body Temperature. Case-Control Studies. Female. Heart Rate. Humans. Male. Middle Aged. Probability. Reference Values. Risk Assessment. Safety. Sampling Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Resuscitation. 1998 Jun;37(3):189-95 [9715779.001]
  • [Cites] Adv Cardiol. 1978;25:73-81 [707206.001]
  • [Cites] Neurology. 1971 May;21(5):559-62 [5104101.001]
  • [Cites] Am J Med. 2001 Feb 1;110(2):118-26 [11165553.001]
  • [Cites] Circulation. 1976 Apr;53(4):720-7 [815061.001]
  • [Cites] J Appl Physiol (1985). 2001 Oct;91(4):1529-34 [11568133.001]
  • [Cites] Ann N Y Acad Sci. 1997 Mar 15;813:654-62 [9100952.001]
  • [Cites] Hypertension. 1994 Nov;24(5):556-63 [7960013.001]
  • [Cites] JAMA. 1991 Aug 14;266(6):829-35 [1865522.001]
  • [Cites] Pediatrics. 1990 Aug;86(2):282-8 [2371104.001]
  • [Cites] Am J Cardiol. 1989 Jul 1;64(1):97-9 [2741821.001]
  • [Cites] Arctic Med Res. 1989 Apr;48(2):64-74 [2736002.001]
  • [Cites] Hypertension. 1983 Sep-Oct;5(5 Pt 2):III17-20 [6629458.001]
  • [Cites] Med J Aust. 1980 Jul 12;2(1):39-40 [7432266.001]
  • [Cites] Pharmacol Ther. 2001 May-Jun;90(2-3):179-230 [11578657.001]
  • (PMID = 14662661.001).
  • [ISSN] 0820-3946
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  • [Other-IDs] NLM/ PMC280579
  •  go-up   go-down


31. Field SK, Cowie RL: Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest; 2003 Oct;124(4):1482-6
Hazardous Substances Data Bank. ETHAMBUTOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.
  • BACKGROUND: Mycobacterium avium-intracellulare (MAC) causes progressive lung disease.
  • Recommended treatment regimens include a macrolide and a rifamycin, but drug intolerance and relapse after treatment is completed often limit successful therapy.
  • METHODS: Consecutive individuals referred for treatment of MAC lung disease were treated with a regimen that included either clarithromycin, 500 mg bid, or azithromycin, 250 mg/d, on weekdays; ethambutol, 15 mg/kg/d; and clofazimine, 100 mg/d.
  • The diagnosis of MAC lung disease was confirmed by multiple positive sputum culture findings in patients with typical symptoms and radiologic findings.
  • RESULTS: Thirty patients (27 women and 3 men; mean age, 70 +/- 9.4 years [SD]) were treated.
  • The remaining patients continued treatment for an average of 10 months, and sputum findings converted to negative in all 26 patients (87%).
  • One patient died of unrelated causes while still receiving therapy, and five patients (19%) relapsed an average of 17 months after treatment was completed.
  • CONCLUSIONS: Treatment with a macrolide, ethambutol, and clofazimine was successful in 20 of 30 patients (67%) with MAC lung disease and is a reasonable alternative to rifamycin-containing regimens.
  • [MeSH-major] Antitubercular Agents / therapeutic use. Clofazimine / therapeutic use. Ethambutol / therapeutic use. Leprostatic Agents / therapeutic use. Lung Diseases / drug therapy. Lung Diseases / microbiology. Mycobacterium avium-intracellulare Infection / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Therapy, Combination. Female. Humans. Macrolides / therapeutic use. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycobacterium Avium Complex.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14555583.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / Leprostatic Agents; 0 / Macrolides; 8G167061QZ / Ethambutol; D959AE5USF / Clofazimine
  •  go-up   go-down


32. Ito T, Suwa M, Kobashi A, Nakamura T, Miyazaki S, Imai M, Kitaura Y: Influence of propranolol infusion on cyclic variation of myocardial integrated backscatter in hypertrophic obstructive cardiomyopathy. J Am Soc Echocardiogr; 2002 Oct;15(10 Pt 2):1251-5
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Before and after 2 mg propranolol infusion, transthoracic echocardiography with integrated backscatter analysis was performed on 11 patients (8 men and 3 women, mean age 54 +/- 12 years old).
  • [MeSH-major] Adrenergic beta-Antagonists / administration & dosage. Cardiomyopathy, Hypertrophic / drug therapy. Cardiomyopathy, Hypertrophic / physiopathology. Myocardial Contraction / drug effects. Myocardial Contraction / physiology. Propranolol / administration & dosage
  • [MeSH-minor] Adult. Aged. Blood Pressure / drug effects. Blood Pressure / physiology. Echocardiography. Female. Heart Rate / drug effects. Heart Rate / physiology. Heart Ventricles / drug effects. Heart Ventricles / ultrasonography. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome. Ventricular Function, Left / drug effects. Ventricular Function, Left / physiology

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12411913.001).
  • [ISSN] 0894-7317
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


33. Marchionatti AM, Picotto G, Narvaez CJ, Welsh J, Tolosa de Talamoni NG: Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J Steroid Biochem Mol Biol; 2009 Feb;113(3-5):227-32
Hazardous Substances Data Bank. MENADIONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Menadione (MEN), a glutathione (GSH)-depleting compound, may potentiate antitumoral effects of anticancer drugs.
  • The aim of this study was to investigate whether MEN enhances cellular responsiveness of MCF-7 cells to 1,25(OH)(2)D(3).
  • Cells were cultured and treated with different concentrations of 1,25(OH)(2)D(3)+/-MEN or vehicle for 96 h.
  • Both drugs decreased growth and enhanced ROS in MCF-7 cells, obtaining the maximal effects when 1,25(OH)(2)D(3) was combined with MEN (P<0.01 vs. Control and vs. each compound alone).
  • MCF-7(DRes) cells were not responsive to 1,25(OH)(2)D(3), but the cell proliferation was slightly inhibited by the combined treatment.
  • Calcitriol and MEN separately enhanced antioxidant enzyme activities, but when they were used in combination, the effect was more pronounced (P<0.05 vs. Control and vs. each compound alone).
  • MEN, calcitriol and the combined treatment decreased GSH levels (P<0.05 vs. Control).
  • The data indicate that MEN potentiates the effect of 1,25(OH)(2)D(3) on growth arrest in MCF-7 cells by oxidative stress and increases the activities of antioxidant enzymes, probably as a compensatory mechanism.
  • [MeSH-major] Breast Neoplasms / drug therapy. Calcitriol. Cell Line, Tumor / drug effects. Vitamin K 3. Vitamins
  • [MeSH-minor] Animals. Antioxidants / metabolism. Cell Shape / drug effects. Dose-Response Relationship, Drug. Drug Synergism. Female. Humans. Oxidative Stress. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vitamins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19429426.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Reactive Oxygen Species; 0 / Vitamins; 723JX6CXY5 / Vitamin K 3; FXC9231JVH / Calcitriol
  •  go-up   go-down


34. Bergua C, Torregrosa JV, Cofán F, Oppenheimer F: Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc; 2007 Sep;39(7):2254-5
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism.
  • Thirteen renal transplanted patients (10 women and 3 men) were included based upon: a total serum calcium >10.5 mg/dL; intact PTH (iPTH) blood levels >65 pg/mL; graft function >6 months, and stable maintenance immunosuppressive therapy.
  • The mean time of initiation was 64 +/- 7 months after transplantation.
  • There were no significant changes in blood levels of alkaline phosphatase, magnesium, bicarbonate, calciuria, phosphaturia, and immunosuppressive drugs.
  • [MeSH-major] Hypercalcemia / prevention & control. Hyperparathyroidism, Secondary / drug therapy. Kidney Failure, Chronic / complications. Kidney Transplantation / adverse effects. Naphthalenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889155.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Naphthalenes; 1K860WSG25 / Cinacalcet Hydrochloride
  •  go-up   go-down


35. Farmakiotis D, Farmakis C, Rousso D, Kourtis A, Katsikis I, Panidis D: The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. Fertil Steril; 2007 Oct;88(4):847-53
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia.
  • PATIENT(S): One-hundred subfertile men with idiopathic oligozospermia.
  • INTERVENTION(S): Toremifene (60 mg daily) was administered to all men for 3 months.
  • At baseline and at the end of each month, serum concentrations of follicle-stimulating hormone (FSH), testosterone, inhibin B, and sex hormone-binding globulin (SHBG) were measured.
  • At baseline and at the end, semen analysis was performed and sperm concentration, spermatozoal motility and normal sperm forms were determined.
  • Twenty-two men's partners achieved pregnancy within 2 months of the end of treatment.
  • At the end of the third month, serum FSH levels were significantly higher in the men whose partners did not achieve pregnancy, and total sperm count and normal sperm forms were significantly lower compared with the group of men whose partners achieved pregnancy.
  • CONCLUSION(S): Toremifene administration for a period of 3 months in men with idiopathic oligozoospermia is associated with significant improvements of sperm count, motility, and morphology, mediated by increased gonadotropin secretion and possibly a direct beneficial effect of toremifene on the testes.
  • The above findings are also indicative of a better testicular exocrine (improved sperm parameters) response to treatment in men whose partners achieved pregnancy compared with those who did not.
  • Further randomized, placebo-controlled trials should be conducted to determine whether this particular selective estrogen receptor modulator can be useful as an initial approach in men with oligozoospermia.
  • [MeSH-major] Hypothalamo-Hypophyseal System / drug effects. Oligospermia / drug therapy. Selective Estrogen Receptor Modulators / therapeutic use. Spermatozoa / drug effects. Testis / drug effects. Toremifene / therapeutic use
  • [MeSH-minor] Adult. Female. Follicle Stimulating Hormone / blood. Humans. Inhibins / blood. Male. Middle Aged. Pregnancy. Pregnancy Rate. Semen / cytology. Sex Hormone-Binding Globulin / analysis. Sperm Motility / drug effects. Testosterone / blood

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17412336.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 0 / Sex Hormone-Binding Globulin; 0 / inhibin B; 3XMK78S47O / Testosterone; 57285-09-3 / Inhibins; 7NFE54O27T / Toremifene; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


36. Czito BG, Kelsey CR, Hurwitz HI, Willett CG, Morse MA, Blobe GC, Fernando NH, D'Amico TA, Harpole DH, Honeycutt W, Yu D, Bendell JC: A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):1002-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
  • PURPOSE: Concurrent chemotherapy and radiation therapy (RT) are used to treat patients with esophageal cancer.
  • METHODS AND MATERIALS: Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received capecitabine, carboplatin, and paclitaxel with RT (1.8 Gy daily to 50.4 Gy).
  • RESULTS: Thirteen patients were enrolled (10 men, 3 women).
  • Overall, 3 of 10 patients at dose level -1 developed DLT (2 Grade 3 esophagitis, 1 Grade 3 hypotension).
  • CONCLUSIONS: The maximally tolerated/recommended phase II doses were capecitabine 600 mg/m(2) twice daily, carboplatin AUC 1.5 weekly, and paclitaxel 45 mg/m(2) weekly with RT to 50.4 Gy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Area Under Curve. Capecitabine. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy / methods. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197129.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Prabhakar MM, Acharya AJ, Modi DR, Jadav B: Spinal hydatid disease: a case series. J Spinal Cord Med; 2005;28(5):426-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal hydatid disease: a case series.
  • BACKGROUND: Over the past 10 years, 4 cases of spinal hydatid disease (3 men, 1 woman) were diagnosed and treated at our institution, with an average follow-up of 4 years.
  • Hydatid disease of the spine is a rare condition with a poor prognosis that presents diagnostic and therapeutic challenges.
  • Decompressive surgeries were performed and the diagnosis was confirmed by histopathologic examination.
  • All patients received long-term antihelminthic therapy with 400 mg of albendazole 3 times daily for 1 year.
  • RESULTS: After surgery, all patients improved; however, over time, recurrence and residual disease were observed.
  • The other 2 patients did not achieve complete neurologic recovery despite anterior decompression; they developed recurrent disease and the neurologic status deteriorated to spastic paraplegia.
  • CONCLUSION: Diagnosis was challenging, eradication was difficult, and hydatid disease recurred in all 4 patients.
  • [MeSH-major] Echinococcosis / diagnosis. Echinococcosis / drug therapy. Echinococcus granulosus / isolation & purification. Spinal Cord Diseases / parasitology. Spine / parasitology
  • [MeSH-minor] Adult. Albendazole / therapeutic use. Anthelmintics / therapeutic use. Decompression, Surgical. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Paraplegia / etiology. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Egypt Soc Parasitol. 1999 Aug;29(2):547-50 [10605504.001]
  • [Cites] J Radiol. 1999 Feb;80(2):147-9 [10209711.001]
  • [Cites] World J Surg. 2001 Jan;25(1):75-82 [11213159.001]
  • [Cites] Ann Thorac Surg. 2001 Jan;71(1):372-3 [11216791.001]
  • [Cites] Arch Orthop Trauma Surg. 2003 Apr;123(2-3):107-11 [12677439.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Jul;105(3):209-14 [12860516.001]
  • [Cites] Scand J Infect Dis. 2003;35(6-7):394-6 [12953951.001]
  • [Cites] Clin Radiol. 1980 May;31(3):287-90 [7428267.001]
  • [Cites] Radiology. 1981 Sep;140(3):763-6 [7280247.001]
  • [Cites] AJR Am J Roentgenol. 1985 Sep;145(3):639-48 [3895873.001]
  • [Cites] Radiology. 1987 Feb;162(2):571-2 [3797674.001]
  • [Cites] Radiology. 1990 Jun;175(3):701-6 [2343117.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jan-Feb;17(1):80-5 [8419444.001]
  • [Cites] Infection. 1997 Jul-Aug;25(4):221-6 [9266261.001]
  • [Cites] Acta Orthop Scand. 1998 Feb;69(1):89-94 [9524526.001]
  • [Cites] Spinal Cord. 1998 Mar;36(3):166-70 [9554015.001]
  • [Cites] Eur Spine J. 1998;7(2):158-61 [9629941.001]
  • [Cites] Eur Spine J. 1998;7(2):162-4 [9629942.001]
  • [Cites] Radiographics. 2000 May-Jun;20(3):795-817 [10835129.001]
  • (PMID = 16869090.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthelmintics; F4216019LN / Albendazole
  • [Number-of-references] 22
  • [Other-IDs] NLM/ PMC1808269
  •  go-up   go-down


38. Wang AA, Hutchinson DT: The effect of corticosteroid injection for trigger finger on blood glucose level in diabetic patients. J Hand Surg Am; 2006 Jul-Aug;31(6):979-81
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients had type I (juvenile-onset) diabetes and 12 patients had type II (adult-onset) diabetes.
  • RESULTS: There were 3 men and 15 women with an average age of 58 years.
  • This trend was marked particularly in type I diabetic patients, who had an average blood glucose level increase the first morning after injection of 145%, which decreased over 5 days to 22% greater than baseline levels.
  • CONCLUSIONS: A digital injection of the corticosteroid methylprednisolone acetate in diabetic patients with trigger finger causes a hyperglycemic effect that lasts for at least 5 days but can help prevent the need for surgery more than half the time.
  • TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic, Level IV.
  • [MeSH-major] Blood Glucose / drug effects. Diabetes Mellitus, Type 1 / blood. Diabetes Mellitus, Type 2 / blood. Hyperglycemia / chemically induced. Methylprednisolone / analogs & derivatives. Trigger Finger Disorder / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Glucose Self-Monitoring. Female. Humans. Injections. Male. Middle Aged. Prospective Studies. Tendons / drug effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16843159.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 43502P7F0P / methylprednisolone acetate; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


39. Hsu JT, Yeh CN, Chen YR, Chen HM, Hwang TL, Jan YY, Chen MF: Adenosquamous carcinoma of the pancreas. Digestion; 2005;72(2-3):104-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Adenosquamous carcinoma (ASC) of the pancreas is rare and correct preoperative diagnosis is difficult.
  • This study investigated the clinicopathological features of 7 cases of ASC of the pancreas and reviewed the pertinent literature to elucidate this rare disease.
  • METHODOLOGY: Seven patients (4 men and 3 women; age range 38-79 years; median 66 years) with ASC of the pancreas who underwent surgical treatment at Chang Gung Memorial Hospital between February 1993 and April 2000 were retrospectively reviewed.
  • The tumors were located at the head of the pancreas in 4 patients (57.1%), at the body in 2, and at the tail in 2.
  • Three patients received postoperative adjuvant chemotherapy.
  • Most patients had dismal prognosis despite aggressive surgery with or without adjuvant therapy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pancreatectomy. Pancreaticoduodenectomy. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16172546.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


40. la Porte C, Verweij-van Wissen C, van Ewijk N, Aarnoutse R, Koopmans P, Reiss P, Stek M Jr, Hekster Y, Burger D: Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. J Clin Pharmacol; 2005 Feb;45(2):211-8
Hazardous Substances Data Bank. DIDEOXYINOSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because these drugs are frequently included in 1 regimen, the food effects on the pharmacokinetics were evaluated.
  • Statistical comparisons of test regimens C and D with reference regimens A and B were made using the equivalence approach for indinavir and didanosine area under the curve and C(max) (0.80-1.25).
  • Eight subjects (5 men, 3 women) were enrolled and completed the study.
  • [MeSH-major] Delayed-Action Preparations. Didanosine / pharmacokinetics. Drug Interactions. Indinavir / pharmacokinetics. Ritonavir / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adult. Area Under Curve. Capsules. Cross-Over Studies. Drug Administration Schedule. Drug Therapy, Combination. Female. Food-Drug Interactions. Half-Life. Healthy Volunteers. Humans. Male. Reproducibility of Results. Therapeutic Equivalency

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. INDINAVIR SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647414.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsules; 0 / Delayed-Action Preparations; 5W6YA9PKKH / Indinavir; K3GDH6OH08 / Didanosine; O3J8G9O825 / Ritonavir
  •  go-up   go-down


41. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, Katznelson L, Weber TJ, Friedman TC, Snyder P, Levine HL: New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab; 2004 Aug;89(8):3821-9
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
  • A new mucoadhesive testosterone buccal system (Striant), 30 mg testosterone (T), was applied twice daily in 82 hypogonadal men for 3 months.
  • The mean percentage of time over a 24-h period that total serum T concentrations were above the lower limit of adult male range was 80.1%.
  • During treatment, mean serum 5alpha-dihydrotestosterone, free T, and estradiol concentrations paralleled serum T.
  • T pharmacokinetics were not significantly affected by body mass index, age, food or beverage, gum abnormalities, or medications known to cause dry mouth.
  • Except for three subjects, the gum adverse effects occurred early during treatment, did not cause interruption of treatment, and resolved rapidly and completely.
  • The T buccal system is a novel T formulation that offers a safe, effective, and convenient alternative to existing formulations for physiological T replacement therapy in hypogonadal men.
  • [MeSH-major] Androgens / administration & dosage. Androgens / blood. Cheek. Drug Delivery Systems. Hypogonadism / blood. Hypogonadism / drug therapy. Testosterone / administration & dosage. Testosterone / blood
  • [MeSH-minor] Adult. Aged. Aging / blood. Body Mass Index. Dihydrotestosterone / blood. Drug Administration Schedule. Estradiol / blood. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Male. Middle Aged. Mouth Mucosa. Osmolar Concentration. Patient Acceptance of Health Care. Patient Compliance. Tissue Adhesives

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15292312.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR00425
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Tissue Adhesives; 08J2K08A3Y / Dihydrotestosterone; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


42. Taniguchi Y, Ueshima K, Chiba I, Segawa I, Kobayashi N, Saito M, Hiramori K: A new method using pulmonary gas-exchange kinetics to evaluate efficacy of beta-blocking agents in patients with dilated cardiomyopathy. Chest; 2003 Sep;124(3):954-61
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND PATIENTS: The exercise capacity of 12 patients (9 men and 3 women; mean +/- SD age, 54 +/- 12 years; New York Heart Association class I [n = 1], NYHA class 2 [n = 4], and NYHA class III [n = 6]) with DCM, who were treated with beta-blocking agents, was evaluated by CPX.
  • Peak O(2) (20.4 +/- 5.1 to 18.8 +/- 5.8 mL/min/kg), AT (12.7 +/- 3.5 to 12.1 +/- 2.1 mL/min/kg), and exercise time (4.8 +/- 2.2 to 4.5 +/- 2.1 s) were unchanged.
  • The time constant of O(2) kinetics (tau) on response to constant low-dose work loading (warm up) decreased significantly (64 +/- 30 to 44 +/- 24 s; p < 0.01) and ejection fraction increased (30 +/- 14 to 44 +/- 15%, p < 0.01) significantly following treatment with beta-blocking agents.
  • Although indexes of total exercise time and AT were not useful markers for clinical improvement in cardiac performance as assessed by echocardiography, measuring can validly assess the beneficial effects in heart failure treated with beta-blocking agents.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Cardiomyopathy, Dilated / drug therapy. Exercise Test / drug effects. Pulmonary Gas Exchange / drug effects. Ventricular Dysfunction, Left / drug therapy
  • [MeSH-minor] Adult. Aged. Atenolol / adverse effects. Atenolol / therapeutic use. Blood Pressure / drug effects. Carteolol / adverse effects. Carteolol / therapeutic use. Dose-Response Relationship, Drug. Drug Therapy, Combination. Echocardiography / drug effects. Female. Heart Rate / drug effects. Humans. Male. Metoprolol / adverse effects. Metoprolol / therapeutic use. Middle Aged. Oxygen / blood. Treatment Outcome. Ventricular Function, Left / drug effects

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Dilated Cardiomyopathy.
  • Hazardous Substances Data Bank. ATENOLOL .
  • Hazardous Substances Data Bank. METOPROLOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12970023.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 50VV3VW0TI / Atenolol; 8NF31401XG / Carteolol; GEB06NHM23 / Metoprolol; S88TT14065 / Oxygen
  •  go-up   go-down


43. Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care; 2003 Aug;26(8):2268-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We evaluated the renoprotective effects as reflected by short-term changes in albuminuria of dual blockade of the renin-angiotensin system (RAS) by adding an angiotensin II receptor blocker (ARB) to treatment with maximal recommended doses of an ACE inhibitor (ACEI) in patients with type 2 diabetes and nephropathy.
  • RESEARCH DESIGN AND METHODS: A total of 20 patients (17 men and 3 women) with type 2 diabetes along with hypertension and nephropathy were enrolled in this double-blind, randomized, two-period, crossover trial of 8 weeks of treatment with the ARB candesartan 16 mg daily and placebo added in random order to existing treatment with lisinopril/enalapril 40 mg daily or captopril 150 mg daily.
  • At the end of each treatment period, we evaluated albuminuria in three 24-h urinary collections by turbidimetry, 24-h ambulatory blood pressure (ABP) using the Takeda-TM2420, and glomerular filtration rate (GFR) by the (51)Cr-EDTA plasma-clearance technique.
  • RESULTS: During monoblockade of the RAS by ACEI treatment, albuminuria was 706 (349-1,219) mg/24 h [geometric mean (IQR)]; 24-h ABP was 138 +/- 3/72 +/- 2 mmHg (mean +/- SE); and GFR was 77 +/- 6 ml x min(-1) x 1.73 m(-2) (mean +/- SE).
  • There was a modest reduction in systolic/diastolic 24-h ABP of 3/2 mmHg (-2 to 8 systolic, -2 to 5 diastolic; NS).
  • CONCLUSIONS: Dual blockade of the RAS provides superior short-term renoprotection independent of systemic blood pressure changes in comparison with maximally recommended doses of ACEI in patients with type 2 diabetes as well as nephropathy.
  • [MeSH-major] Angiotensin Receptor Antagonists. Angiotensin-Converting Enzyme Inhibitors / administration & dosage. Antihypertensive Agents / administration & dosage. Benzimidazoles / administration & dosage. Diabetic Nephropathies / drug therapy. Lisinopril / administration & dosage. Tetrazoles / administration & dosage
  • [MeSH-minor] Aged. Captopril / administration & dosage. Cross-Over Studies. Diabetes Mellitus, Type 2 / complications. Double-Blind Method. Drug Therapy, Combination. Enalapril / administration & dosage. Female. Humans. Kidney / drug effects. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • Hazardous Substances Data Bank. CANDESARTAN .
  • Hazardous Substances Data Bank. CAPTOPRIL .
  • Hazardous Substances Data Bank. LISINOPRIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12882847.001).
  • [ISSN] 0149-5992
  • [Journal-full-title] Diabetes care
  • [ISO-abbreviation] Diabetes Care
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antihypertensive Agents; 0 / Benzimidazoles; 0 / Tetrazoles; 69PN84IO1A / Enalapril; 9G64RSX1XD / Captopril; E7199S1YWR / Lisinopril; S8Q36MD2XX / candesartan
  •  go-up   go-down


44. Aulas JJ, Rosner I: [Efficacy of a non blind placebo prescription]. Encephale; 2003 Jan-Feb;29(1):68-71
MedlinePlus Health Information. consumer health - Fatigue.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Effets de la prescription d'un placebo "annoncé".
  • The aim of our open clinical trial was to determine the efficacy and the tolerance of a blue coloured placebo in moderated anxious patients (Hamilton score below 15) and a red one for tired patients without DSM IV criteria of major depressive disorder.
  • All the patients knew that treatment was a placebo and so, had no pharmacological effect.
  • At the end of the week, the final clinical evaluation showed that 18 patients about 34 were in good condition (10 anxious patients, 7 women and 3 men, and 8 tired patients, 4 women and 4 men).
  • The anxious score of Hamilton scale was reduced of 63%; 16 of the 18 responders were absolutely sure that the treatment was usefull.
  • Four patients were obliged to stop their treatment because side effects: insomnia, tiredness and sleepiness, gastric pain and itching of fore arm.
  • [MeSH-major] Anxiety / drug therapy. Depressive Disorder, Major / drug therapy. Drug Prescriptions. Fatigue / drug therapy. Placebo Effect. Placebos / adverse effects

  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12640329.001).
  • [ISSN] 0013-7006
  • [Journal-full-title] L'Encéphale
  • [ISO-abbreviation] Encephale
  • [Language] fre
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Placebos
  •  go-up   go-down


45. Díez JJ: Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J Gerontol A Biol Sci Med Sci; 2002 May;57(5):M315-20
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy.
  • Our aim has been to assess the relative frequency of the diverse causes of hypothyroidism in a group of patients older than 55 years and the adequacy of control of thyroid function attained by levothyroxine therapy.
  • From a total of 1581 patients older than 55 who were complaining of a thyroid disorder, we studied a group of 655 patients with hypothyroidism.
  • There were 559 women (85.3%, age 65.01 +/- 7.90 years) and 96 men (14.7%, 65.36 +/- 8.39 years).
  • In every patient, we collected etiology, presence of goiter, time of evolution from diagnosis and from therapy prescription, previous and present treatments, current thyroid functional status (free thyroxine and thyrotropin concentration), adequacy of disease control, and thyroid autoimmune status.
  • RESULTS: The causes of hypothyroidism were as follows: autoimmune thyroiditis, 308 (47.0%); postoperative hypothyroidism, 175 (26.7%); therapy for previous thyrotoxicosis, 63 (9.6%); thyrotropin deficiency, 15 (2.3%); iodine excess, 6 (0.9%); subacute thyroiditis, 2 (0.3%); and unknown etiology, 86 (13.1%) patients.
  • Most patients with autoimmune thyroiditis were positive for thyroid peroxidase antibodies at the time of the study (94.4%).
  • Mean (+/- SD) age at diagnosis was 61.8 +/- 9.4 years in men and 59.8 +/- 9.7 years in women.
  • Median (range) duration of hypothyroidism was 1.4 (0-18) years in men and 3 (0-45) years in women ( p <.05).
  • Adequacy of therapy was studied in 385 patients treated with replacement doses of levothyroxine.
  • Two hundred and sixty (67.5%) of these subjects attained good control, whereas 125 (32.5%) showed inadequate control of the disease at the time of the study.
  • A model of logistic regression showed that adequacy of therapy was dependent on the duration of therapy, but independent of age, gender, degree of hypothyroidism, etiology, autoimmune status, age at diagnosis, and dose of levothyroxine.
  • A 2-year follow-up study performed in 56 newly diagnosed patients showed that an adequate control of hypothyroidism was attained in 35 (62.5%) patients at 6 months, in 46 (82.1%) patients at 1 year, and in 49 (87.5%) at 2 years of therapy with levothyroxine.
  • The time from starting therapy is the main determinant of the adequacy of control of thyroid hypofunction in this population.
  • With effective therapy and appropriate monitoring, more than 80% of the patients showed adequate control within 1 year of follow-up.
  • [MeSH-major] Hypothyroidism / drug therapy. Hypothyroidism / etiology
  • [MeSH-minor] Cross-Sectional Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Thyroid Neoplasms / surgery. Thyroidectomy / adverse effects. Thyroiditis, Autoimmune / complications. Thyroxine / therapeutic use. Time Factors

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11983726.001).
  • [ISSN] 1079-5006
  • [Journal-full-title] The journals of gerontology. Series A, Biological sciences and medical sciences
  • [ISO-abbreviation] J. Gerontol. A Biol. Sci. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  •  go-up   go-down


46. Stücker M, Memmel U, Hoffmann M, Hartung J, Altmeyer P: Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. Dermatology; 2001;203(2):141-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis.
  • BACKGROUND: There are already many effective topical therapies available for use in the treatment of chronic plaque psoriasis.
  • Unfortunately, these treatments are often associated with a rather significant risk of undesirable effects.
  • OBJECTIVE AND METHODS: In this randomized, prospective clinical trial, the effects of the vitamin D(3) analog calcipotriol were evaluated against those of a recently developed vitamin B(12) cream containing avocado oil in an intraindividual right/left-side comparison.
  • The trial population consisted of 13 patients, 10 men and 3 women, with chronic plaque psoriasis.
  • The observation period was 12 weeks; the effects of therapy were assessed on the basis of a PASI score adapted to the right/left-side comparison technique, the subjective evaluations of the investigator and patients and the results of 20-MHz sonography.
  • RESULTS: There was a more rapid development of beneficial effects with the use of calcipotriol in the initial 8 weeks, although differences in effects were significant only at the time point of therapy week 8 (p < 0.05).
  • After 12 weeks, neither the PASI score nor 20-MHz sonography showed significant differences between the two treatments.
  • This would indicate that the vitamin B(12) preparation containing avocado oil may be suitable for use in long-term therapy, a hypothesis further supported by the fact that the investigator and the patients assessed the tolerability of the vitamin B(12) cream containing avocado oil as significantly better in comparison with that of calcipotriol.
  • CONCLUSION: The results of this clinical trial provide evidence that the recently developed vitamin B(12) cream containing avocado oil has considerable potential as a well-tolerated, long-term topical therapy of psoriasis.
  • [MeSH-major] Calcitriol / analogs & derivatives. Persea. Phytotherapy. Plant Oils / therapeutic use. Psoriasis / drug therapy. Vitamin B 12 / therapeutic use
  • [MeSH-minor] Adult. Aged. Dermatologic Agents / adverse effects. Dermatologic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Ointments. Prospective Studies. Pruritus / chemically induced. Severity of Illness Index. Skin / drug effects. Skin / pathology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11586013.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Ointments; 0 / Plant Oils; 143NQ3779B / calcipotriene; FXC9231JVH / Calcitriol; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


47. Günaydin I, Pereira PL, Daikeler T, Mohren M, Trübenbach J, Schick F, Kanz L, Kötter I: Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol; 2000 Feb;27(2):424-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study.
  • OBJECTIVE: To evaluate magnetic resonance imaging (MRI) guided corticosteroid injections of inflamed sacroiliac (SI) joints in patients with spondyloarthropathy with therapy resistant sacroiliitis.
  • METHODS: We performed 16 injections in 9 patients on an outpatient basis (6 men, 3 women, mean age at onset 24.7 +/- 7.5 yrs).
  • CONCLUSION: MRI guided corticosteroid injection of SI joints appears to be an effective and safe procedure without exposure to radiation.
  • It is a useful therapeutic modality, especially in young patients with severe isolated sacroiliitis.
  • [MeSH-major] Adrenal Cortex Hormones / administration & dosage. Arthritis / drug therapy. Sacroiliac Joint / radiography
  • [MeSH-minor] Adolescent. Adult. Child. Drug Resistance. Female. Humans. Magnetic Resonance Imaging. Male. Pilot Projects

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10685809.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] CANADA
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


48. Grañana N, Taddeo P, Espoueys P, Nazer C: [Pubertal behavioral decompensation in patients with pervasive developmental disorders]. Vertex; 2010 May-Jun;21(91):245-9
MedlinePlus Health Information. consumer health - Puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Descompensaciones conductuales puberales en pacientes con trastorno generalizado del desarrollo.
  • METHODS: We analyzed in a prospective study the stories of 11 children and adolescents with ASD, their demographic characteristics, initial symptoms of descompensation at pubertal or adolescence stages, interventions developed and evolution with them.
  • RESULTS: We studied the clinical stories of eleven patients, 8 men and 3 women, who consulted with behavioral descompensation periods at a mean age of 13 years (range 10- 16 years).
  • Almost all patients had received psychiatric medication before descompensation, except patients with catatonia.
  • Eight of 11 patients recovered with psychological and pharmacological (a medium of 2 drugs) interventions in a mean time of 4 months.
  • Both patients with catatonia didn't recovered, and one more patient didn't improved with pharmacological treatment.
  • [MeSH-major] Autistic Disorder. Puberty
  • [MeSH-minor] Adolescent. Catatonia / diagnosis. Child. Female. Follow-Up Studies. Humans. Male. Prospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pervasive Developmental Disorders.
  • Genetic Alliance. consumer health - Behavioral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188302.001).
  • [ISSN] 0327-6139
  • [Journal-full-title] Vertex (Buenos Aires, Argentina)
  • [ISO-abbreviation] Vertex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  •  go-up   go-down


49. Brügemann J, van der Bij W, Verschuuren EA, Klungel AA, van der Horst IC, Erasmus ME, Kerstjens HA, van Veldhuisen DJ, Zijlstra F: [Experiences of combined heart-lung transplantations in the University Medical Center Groningen]. Ned Tijdschr Geneeskd; 2009;153:B98
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The study group consisted of 14 patients (3 men and 11 women) with a mean age of 41 years.
  • Indications for heart-lung transplantation were: congenital heart disease complicated by pulmonary hypertension (6 patients), idiopathic pulmonary hypertension with severe right ventricle failure (4 patients), lung fibrosis with severe right ventricle failure (1 patient), cystic fibrosis with systolic left ventricle failure (1 patient), pulmonary hypertension after thoracic radiation and chemotherapy (1 patient) and re-transplantation after lung-transplant failure (1 patient).
  • The mean waiting time prior to operation was approximately 1.5 years.
  • At the end of the study 6 of the 14 patients (43%) were alive, with a mean survival period of 58 months (range: 6-132).
  • The waiting time in this study was long and the post-transplantation mortality was high.
  • [MeSH-minor] Adult. Cause of Death. Cystic Fibrosis / complications. Cystic Fibrosis / therapy. Female. Heart Diseases / complications. Heart Diseases / therapy. Humans. Hypertension, Pulmonary / complications. Hypertension, Pulmonary / therapy. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Netherlands. Retrospective Studies. Survival Rate. Waiting Lists. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785831.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


50. Koziński M, Bielis L, Wiśniewska-Szmyt J, Sukiennik A, Grabczewska Z, Swiatkiewicz I, Ziołkowski M, Rość D, Kubica J: Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. Cardiol J; 2008;15(6):530-6
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
  • Similarly, enhanced morning platelet aggregation has been observed in healthy individuals and in subjects with coronary artery disease without adequate antiplatelet treatment.
  • The purpose of the study was to assess circadian variation in platelet aggregation in patients with first ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI) and dual antiplatelet therapy.
  • METHODS: Fifteen consecutive patients (12 men and 3 women) were prospectively recruited into the study.
  • CONCLUSIONS: Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first STEMI undergoing pPCI.
  • The clinical significance of this finding remains to be demonstrated.
  • [MeSH-major] Circadian Rhythm / physiology. Electrocardiography. Myocardial Infarction / drug therapy. Platelet Aggregation / drug effects. Platelet Aggregation Inhibitors / therapeutic use
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Anticoagulants / administration & dosage. Anticoagulants / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Routes. Drug Therapy, Combination. Female. Follow-Up Studies. Heparin / administration & dosage. Heparin / therapeutic use. Humans. Immunoglobulin Fab Fragments / administration & dosage. Immunoglobulin Fab Fragments / therapeutic use. Male. Middle Aged. Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors. Ticlopidine / administration & dosage. Ticlopidine / analogs & derivatives. Ticlopidine / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. Abciximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039757.001).
  • [ISSN] 1897-5593
  • [Journal-full-title] Cardiology journal
  • [ISO-abbreviation] Cardiol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Anticoagulants; 0 / Immunoglobulin Fab Fragments; 0 / Platelet Aggregation Inhibitors; 0 / Platelet Glycoprotein GPIIb-IIIa Complex; 9005-49-6 / Heparin; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine; X85G7936GV / abciximab
  •  go-up   go-down


51. Matsushita S, Naito T, Takebayashi M, Sato H, Shiota H: The prognosis of cases with massive subretinal hemorrhage after photodynamic therapy. J Med Invest; 2008 Aug;55(3-4):231-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of cases with massive subretinal hemorrhage after photodynamic therapy.
  • PURPOSE: To investigate cases with massive subretinal hemorrhage after photodynamic therapy (PDT).
  • SUBJECTS AND METHODS: We studied four cases (3 men and 1 woman, mean 80.5 years old) with massive subretinal hemorrhage after PDT about type of disease, spot size, period to the onset of hemorrhage, visual acuity (VA) before and after PDT.
  • RESULTS: Four cases consisted of one with age-related macula degeneration (AMD) and 3 with polypoidal choroidal vasculopathy (PCV).
  • [MeSH-minor] Aged. Aged, 80 and over. Choroid / blood supply. Choroid Diseases / drug therapy. Female. Humans. Macular Degeneration / drug therapy. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797136.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


52. Rosato L, Mondini G, Serbelloni M, Bertone P, Orlassino R, Cossavella D: [Intra-abdominal desmoid tumors: rare but important disease]. G Chir; 2007 Jan-Feb;28(1-2):20-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-abdominal desmoid tumors: rare but important disease].
  • Desmoid tumors are rare benign neoplasms with high tendency to local recurrence, and they can be divided into extra- and intra-abdominal types (mesenteric fibromatosis).
  • Six patients (3 men and 3 women) affected by extra-abdominal desmoid tumors have been treated with radical excision.
  • In both cases the hystological diagnosis has been desmoid tumor.
  • Surgical treatment of desmoid tumors must aim at radical excision to avoid frequent recurrences (25-65%); these have stimulated the research of other kinds of treatments, since a new surgical operation itself can lead to a further recurrence.
  • Radiotherapy has been investigated with results in 79-96% of cases, antiestrogenic therapy has been used with success in 51% of patients, and high dose tamoxifen seemed to obtain a stable disease in non operable cases.
  • Non steroidal anti-inflammatory drugs have been experimented in association with tamoxifen and chemotherapy.
  • Conclusive results on the efficacy of these treatments have not been obtained yet, because of the rarity of the desmoid tumors even in greater Centres.
  • [MeSH-major] Fibromatosis, Abdominal / surgery. Mesentery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Aged. Female. Fibromatosis, Aggressive / surgery. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313728.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Dressler D, Lange M, Bigalke H: Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord; 2005 Dec;20(12):1617-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.
  • With the advent of a commercial preparation of botulinum toxin type B (BT-B) for treatment of cervical dystonia detection of antibodies against BT-B (BT-B-AB) becomes necessary.
  • After exposing the preparation to BT-B 3 ng/ml the time to half-maximal twitch force reduction (paralysis time [PT]) was 69 +/- 4 min (n = 25).
  • The threshold for BT-B-AB detection was 0.4 mU/ml.
  • When sera from 7 patients (4 women, 3 men; age 50.6 +/- 14.2 years) with cervical dystonia (Toronto Western Spasmodic Torticollis Rating Scale score, 18.9 +/- 2.9) and complete secondary failure of BT-B therapy (NeuroBloc; Elan Pharmaceuticals, Shannon, Ireland; 12,229 +/- 2,601 MU/injection series, 1.86 +/- 0.69 injection series before complete secondary therapy failure; 100.4 +/- 15.8 days between injection series with normal therapeutic effect) were tested, BT-B-AB titers of more than 10 mU/ml were found in all of them.
  • Further studies are necessary to understand the role of intermediate BT-B-AB titers in partial BT-B therapy failure.
  • [MeSH-minor] Animals. Biological Assay / methods. Botulinum Toxins, Type A. Dose-Response Relationship, Drug. Drug Interactions. Female. Humans. Male. Mice. Middle Aged. Time Factors. Treatment Failure

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078216.001).
  • [ISSN] 0885-3185
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Dyskinesia Agents; 0 / Antibodies; 0Y70779M1F / rimabotulinumtoxinB; EC 3.4.24.69 / Botulinum Toxins; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


54. Higa S, Tai CT, Lin YJ, Liu TY, Lee PC, Huang JL, Yuniadi Y, Huang BH, Hsieh MH, Lee SH, Kuo JY, Lee KT, Chen SA: Mechanism of adenosine-induced termination of focal atrial tachycardia. J Cardiovasc Electrophysiol; 2004 Dec;15(12):1387-93
Hazardous Substances Data Bank. Adenosine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: The study consisted of 7 patients (4 men and 3 women; age 44 +/- 29 years) with focal AT.
  • In termination episodes, adenosine significantly decreased the peak negative voltage of AT-O (-27.2 +/- 15.3%, P < 0.01), preferential conduction (proximal: -32.1 +/- 18.7, mid: -28.4 +/- 22.8, distal portion: -29.6 +/- 21.4%, P < 0.01), and breakout (-31.4 +/- 12.5%, P < 0.01).
  • [MeSH-major] Adenosine / therapeutic use. Anti-Arrhythmia Agents / therapeutic use. Tachycardia, Supraventricular / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catheter Ablation. Electrocardiography. Female. Humans. Injections. Male. Middle Aged. Statistics, Nonparametric. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cardiovasc Electrophysiol. 2004 Dec;15(12):1394-5 [15610285.001]
  • (PMID = 15610284.001).
  • [ISSN] 1045-3873
  • [Journal-full-title] Journal of cardiovascular electrophysiology
  • [ISO-abbreviation] J. Cardiovasc. Electrophysiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; K72T3FS567 / Adenosine
  •  go-up   go-down


55. Subasi M, Bukte Y, Kapukaya A, Gurkan F: Tuberculosis of the metacarpals and phalanges of the hand. Ann Plast Surg; 2004 Nov;53(5):469-72
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report their experience with treatment and outcome of TB of the metacarpals and phalanges of the hand in 7 patients.
  • There were 4 women and 3 men in the study who ranged in age from 3 to 60 years (average age, 22.7 years).
  • No patient had an active tubercular lesion or history of pulmonary disease.
  • The diagnosis was based on the clinical picture and radiographic features, and was confirmed by open biopsy.
  • The treatment of all patients began with a 4-drug regimen for 2 months, followed by a 2-drug regimen for 10 months.
  • At the time of the last follow-up, all lesions had healed with no recurrence.
  • It is necessary to keep TB in mind when making the differential diagnosis of several osseous pathologies.
  • [MeSH-major] Hand. Tuberculosis, Osteoarticular / diagnosis
  • [MeSH-minor] Adult. Antitubercular Agents / therapeutic use. Child. Drug Therapy, Combination. Female. Fingers. Follow-Up Studies. Humans. Male. Metacarpus. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502464.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


56. Breilh D, Boselli E, Bel JC, Chassard D, Saux MC, Allaouchiche B: Diffusion of cefepime into cancellous and cortical bone tissue. J Chemother; 2003 Apr;15(2):134-8
MedlinePlus Health Information. consumer health - Bone Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion of cefepime into cancellous and cortical bone tissue.
  • The degree of penetration of an antibiotic into the infection site is an important factor in its therapeutic efficacy, particularly in bone and joint infections.
  • In the present study, we examined the bone tissue penetration of cefepime at a dose of 2 g, and the results were correlated to microbiological data to estimate the clinical efficacy of cefepime in bone infections.
  • Plasma samples were collected simultaneously with bone tissue samples 1.5 hours later, on average, and analyzed by a validated high performance liquid chromatography assay.
  • Ten patients (7 women and 3 men; mean age, 78 years; mean body weight, 57 Kg; mean creatinine clearance, 56 mL/min) were enrolled.
  • The mean +/- SD plasma concentration of cefepime at the time of bone removal was 72.9 +/- 24.4 microg/mL.
  • The mean +/- SD cefepime concentrations were 73.5 +/- 16.2 microg/mL in cancellous bone tissue and 67.7 +/- 17.0 microg/mL in cortical bone tissue.
  • The mean +/- SD ratios of cefepime concentration in bone and plasma (bone/plasma) were 1.06 +/- 0.23 for cancellous bone tissue and 0.87 +/- 0.37 for cortical bone tissue.
  • Cefepime exhibits an excellent diffusion into bone tissue, with concentrations achieved in both cancellous and cortical bone tissue greater than the minimum concentrations required to inhibit the growth of 90% of strains (MIC90) of most of the susceptible pathogens commonly involved in bone infections.
  • [MeSH-major] Bone Diseases, Infectious / drug therapy. Bone and Bones / chemistry. Cephalosporins / pharmacokinetics
  • [MeSH-minor] Aged. Aged, 80 and over. Diffusion. Female. Humans. Male. Microbial Sensitivity Tests. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12797389.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cephalosporins; 807PW4VQE3 / cefepime
  •  go-up   go-down


57. Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M: A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. Laryngoscope; 2000 Oct;110(10 Pt 1):1617-22
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological and immunohistochemical findings, patient demographics, treatment regimens, and outcomes were analyzed and compared.
  • RESULTS: Ten patients (7 men, 3 women) ranging in age from 17 to 58 years (mean age, 44.7 y) were included.
  • Disease in four patients was clinically staged as N1 (three with SNUC, one with SNEC), and in six patients as NO (three with SNEC, three with SNUC).
  • Of the nine patients who were treated initially with surgical resection, seven received postoperative radiation therapy alone, one received postoperative radiation and chemotherapy, and one had only limited postoperative chemotherapy.
  • One patient was treated with radiation therapy and chemotherapy alone, without surgical resection.
  • Three patients died of disease 10, 14, and 41 months, respectively, after diagnosis.
  • Three patients had persistent disease at 6, 9, and 21 months, respectively, two of them with distant metastases.
  • Four patients were disease free after 6, 18, 31, and 108 months, respectively.
  • CONCLUSIONS: SNUC and SNEC are both aggressive tumors, usually presenting in middle age as a nasal mass.
  • Both tumors have the capacity to metastasize locally and distantly, and both can result in poor outcomes.
  • [MeSH-major] Carcinoma / pathology. Nose Neoplasms / pathology. Paranasal Sinuses
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11037813.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


58. Morawiec-Bajda A, Wasilewski B: [Myogenic vestibular evoked potentials used to objective estimation of effectiveness of central action drugs]. Otolaryngol Pol; 2000;54(3):327-36
Hazardous Substances Data Bank. PICROTOXIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myogenic vestibular evoked potentials used to objective estimation of effectiveness of central action drugs].
  • In this paper possibility of employing vestibular evoked myogenic potentials (VEMPs) was evaluated to following efficacy of drug effect in patients with central and peripheral vestibular disorders of various aetiologies.
  • Treatment concerned 23 ills that is 20 women and 3 men in age from 20 to 68 years, average age being 46,82 years.
  • The studied population included 8 patients were diagnosed to have Meniere's disease, 5 ills suffered from neuronitis vestibularis, 5 patients complained of vertigo of vertebrobasilar arterial insufficiency.
  • 3 patients were diagnosed to have vertigo after head trauma, 1 patient suffered from benign paroxysmal positional vertigo and one's cause of disease was unknown.
  • Registration of VEMPs was done in all patients treated before starting and after stopping therapy.
  • Using sublingually of Vertigoheel distinct greater amplitudes were observed in significant numbers of patients after therapy.
  • [MeSH-major] Evoked Potentials / physiology. Meniere Disease / drug therapy. Meniere Disease / physiopathology. Vestibule, Labyrinth / physiopathology
  • [MeSH-minor] Adult. Aged. Central Nervous System Agents / therapeutic use. Drug Combinations. Female. Humans. Male. Middle Aged. Minerals / therapeutic use. Phytotherapy. Picrotoxin / therapeutic use. Plant Extracts / therapeutic use. Plants, Medicinal / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Meniere's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10917061.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  • [Chemical-registry-number] 0 / Central Nervous System Agents; 0 / Drug Combinations; 0 / Minerals; 0 / Plant Extracts; 0 / Vertigoheel; 124-87-8 / Picrotoxin
  •  go-up   go-down


59. Iwamoto J, Uzawa M, Sato Y, Takeda T, Matsumoto H: Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients. J Bone Miner Metab; 2010 Mar;28(2):202-8
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alendronate decreases the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX; about 45% at 3 months) and serum levels of alkaline phosphatase (ALP; about 27% at 24 months), leading to an increase in lumbar spine bone mineral density (BMD; about 9% at 24 months) in postmenopausal Japanese women with osteoporosis.
  • Sixteen patients (3 men and 13 postmenopausal women) with osteoporosis, who had undergone a gastrectomy (mean age: 69.1 years), were recruited in our outpatient clinic.
  • The effects of alendronate on lumbar spine (women) or total hip (men) BMD and urinary NTX and serum ALP levels were examined.
  • With alendronate therapy, urinary NTX levels significantly decreased at 3 months (-27.0%).
  • No severe adverse events were observed, and alendronate therapy was well tolerated.
  • [MeSH-major] Alendronate / therapeutic use. Bone Density / drug effects. Bone Density Conservation Agents / therapeutic use. Bone Remodeling / drug effects. Gastrectomy. Osteoporosis / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Alkaline Phosphatase / blood. Biomarkers. Bone and Bones / chemistry. Bone and Bones / diagnostic imaging. Bone and Bones / drug effects. Collagen / urine. Female. Humans. Longitudinal Studies. Male. Middle Aged. Patient Dropouts. Radiography. Sex Characteristics. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Calcium. 2003 Nov;13(11):1399-404 [15775224.001]
  • [Cites] Clin Pharmacokinet. 1999 May;36(5):315-28 [10384857.001]
  • [Cites] J Pharm Sci. 1994 Dec;83(12):1741-6 [7891304.001]
  • [Cites] Expert Opin Pharmacother. 2007 Nov;8(16):2743-56 [17956196.001]
  • [Cites] J Bone Miner Metab. 2001;19(6):331-7 [11685647.001]
  • [Cites] Am J Med. 1996 Nov;101(5):488-501 [8948272.001]
  • [Cites] J Orthop Sci. 2003;8(5):717-20 [14557940.001]
  • [Cites] Nutrition. 1999 Sep;15(9):677-82 [10467612.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1212-21 [11238511.001]
  • [Cites] J Bone Miner Metab. 2005;23(5):382-8 [16133688.001]
  • [Cites] World J Gastroenterol. 2007 Dec 28;13(48):6492-7 [18161918.001]
  • [Cites] Bone. 1999 May;24(5 Suppl):73S-79S [10321934.001]
  • [Cites] Clin Pharmacol Ther. 1995 Sep;58(3):288-98 [7554702.001]
  • [Cites] J Bone Miner Metab. 2005;23(2):97-104 [15750686.001]
  • [Cites] Clin Interv Aging. 2008;3(3):483-9 [18982918.001]
  • [Cites] J Bone Miner Metab. 2007;25(5):302-9 [17704995.001]
  • [Cites] Hum Nutr Clin Nutr. 1986 Jul;40(4):301-8 [3744890.001]
  • [Cites] Arq Gastroenterol. 2001 Apr-Jun;38(2):129-31 [11793943.001]
  • [Cites] Osteoporos Int. 1999;10(3):183-92 [10525709.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Nov-Dec;7(6):639-45 [1486191.001]
  • [Cites] Curr Med Res Opin. 2006 May;22(5):919-28 [16709313.001]
  • (PMID = 19690798.001).
  • [ISSN] 1435-5604
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Bone Density Conservation Agents; 0 / urinary N-telopeptide of type I collagen, human; 9007-34-5 / Collagen; EC 3.1.3.1 / Alkaline Phosphatase; X1J18R4W8P / Alendronate
  •  go-up   go-down


60. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M: S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology; 2007 Dec;54(80):2315-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas.
  • BACKGROUND/AIMS: 5-FU plus Cisplatin combination therapy had been employed against primary liver carcinomas for years.
  • We herein examined the effect and adverse effects of S-1 plus Cisplatin combination therapy for primary liver carcinomas.
  • METHODOLOGY: 4 patients with hepatocellular carcinoma (HCC) and 3 with cholangiocellular carcinoma (CCC) were employed for this study.
  • They all had far-advanced diseases in and/or out of the liver at the time of the therapy initiation.
  • They were 4 men and 3 women.
  • The protocol of the therapy is a 3-week period of S-1 (70-80 mg/m2/day) oral administration combined with 2 intravenous administration of CDDP (20-35 mg/m2) during the period.
  • With two weeks of intermission, the therapy was repeatedly performed 2-11 times for each patient.
  • RESULTS: Three patients had PR and 2 had NC response with the therapy.
  • Two patients with HCC and pre-treatment with 5-FU had PD response.
  • Although the patients developed leukopenia and thrombocytopenia, the therapy was well tolerable also in the outpatient basis.
  • CONCLUSIONS: S-1 plus Cisplatin combination therapy is a potential therapy for advanced primary liver carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Oxonic Acid / administration & dosage. Prognosis. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265655.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


61. Komori M, Tanaka M, Muramoto E, Ohno M, Matsumoto R, Murase N, Kitagawa N, Saida T: [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis]. Rinsho Shinkeigaku; 2007 Jul;47(7):401-6
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
  • We retrospectively evaluated the benefits of mitoxantrone (MITX) treatment in Japanese patients with multiple sclerosis (MS) with more than 3 relapses per year or a deterioration of more than one Expanded Disability Status Scale (EDSS) of Kurtzke score per year despite having IFN beta 1b therapy.
  • Monthly intravenous injections of MITX, 10-12 mg/m2, for 3 months were followed by an additional treatment every 3 months.
  • Nine patients (6 women, 3 men) with a mean age of 39 years, a mean disease duration of 3.9 years, and a mean EDSS score of 6.7 were studied.
  • Most patients tolerated the treatment, although 2 patients stopped MITX therapy after 3 injections because of severe appetite loss.
  • The 7 patients who continued MITX therapy for more than 3 times significantly decreased their relapse rate and EDSS deterioration.
  • The average relapse count in the year preceding initiation of MITX therapy was 4.3 (range: 3-6)/year, EDSS score increased by 2.7 (range: 1-7)/year.
  • The average relapse count was 2.3 (range: 0-4)/year from 0 to 6 months after MITX therapy (p = 0.114), and 1.1 (range: 0-4)/year from 7 to 12 months (p = 0.285).
  • The average EDSS deterioration was -0.4 (range -2-1) from 0 to 6 months after MITX therapy (p = 0.018), and there was no deterioration from 7 to 12 months.
  • For Japanese MS patients, MITX therapy was very effective to suppress relapses without incurring severe adverse events.
  • [MeSH-major] Mitoxantrone / therapeutic use. Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • [MeSH-minor] Adult. Disability Evaluation. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Myelitis / complications. Optic Neuritis / complications. Retrospective Studies

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710882.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


62. Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL: Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther; 2007 Oct;87(10):1325-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical function in men with prostate cancer on androgen deprivation therapy.
  • BACKGROUND AND PURPOSE: Androgen deprivation therapy (ADT) has become an increasingly standard intervention for both early and advanced stages of prostate cancer; however, decreased physical function and hypogonadism have been reported in men receiving ADT.
  • SUBJECTS AND METHODS: Physical function, walking speed, visuomotor performance, gonadal status, body composition, and Comorbidity Disease Index (CMDI) scores were assessed in a cohort of 100 participants that included:.
  • (1) men with prostate cancer who were not on ADT, (2) men with prostate cancer who were on short-term ADT (<6 months), (3) men with prostate cancer who were on long-term ADT (> or =6 months), and (4) control subjects who did not have prostate cancer.
  • Adjusted for covariates, men on long-term ADT walked 0.18 m/s slower than the control subjects.
  • Androgen deprivation therapy did not have a significant effect on visuomotor performance.
  • DISCUSSION AND CONCLUSION: The results suggest that ADT has a significant effect on walking speed and physical performance in men with prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684084.001).
  • [ISSN] 0031-9023
  • [Journal-full-title] Physical therapy
  • [ISO-abbreviation] Phys Ther
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / P30 AG024827; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NIDDK NIH HHS / DK / K24 DK062895; United States / NCRR NIH HHS / RR / M01 RR000056
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


63. Kweon KH, Park BH, Cho CG: The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci; 2007 Feb;22(1):114-6
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism.
  • The effect of L-thyroxine treatment on ECG parameters, such as QT dispersion, in patients with primary hypothyroidism were investigated.
  • This study involved 18 patients (3 men, 15 women, ages: 48+/-18 yr) with primary hypothyroidism.
  • All patients were checked with a standard 12-lead ECG before and after L-thyroxine treatment.
  • The mean L-thyroxine treatment duration was 22+/-2.7 months.
  • The mean thyroid-stimulating hormone levels of patients before and after therapy were 40.2+/-29.8 microU/mL, 3.6+/-4.6 microU/mL (p<0.001) and free-T4 levels were 0.44+/-0.38 ng/dL, 1.51+/-0.39 ng/dL (p<0.001).
  • After L-thyroxine treatment, QT interval (395+/-42 vs. 380+/-24 msec, p<0.05), QTc interval (434+/-32 vs. 417+/-23 msec, p<0.05), QT dispersion (45+/-23 vs. 30+/-13 msec, p=0.008), QTc dispersion (49+/-23 vs. 32+/-14 msec, p=0.005) significantly decreased.
  • Our findings suggest that the thyroid hormone affects ventricular inhomogenicity, and that L-thyroxine replacement therapy may reduce malignant ventricular arrhythmia and sudden cardiac death in primary hypothyroidism.
  • [MeSH-major] Electrocardiography / drug effects. Hypothyroidism / drug therapy. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 2001 Aug;11(8):765-8 [11525269.001]
  • [Cites] Chin Med J (Engl). 2001 Sep;114(9):906-8 [11780378.001]
  • [Cites] J Pharmacol Exp Ther. 1971 Jan;176(1):212-9 [5569633.001]
  • [Cites] Acta Med Scand. 1983;213(3):231-5 [6133415.001]
  • [Cites] Am J Cardiol. 1989 Apr 1;63(12):867-9 [2929445.001]
  • [Cites] Am J Med Sci. 2006 Mar;331(3):154-6 [16538077.001]
  • [Cites] J Cardiovasc Pharmacol. 1991 Nov;18(5):703-10 [1723767.001]
  • [Cites] Circulation. 1992 Nov;86(5):1376-82 [1423949.001]
  • [Cites] Am J Cardiol. 1994 Sep 15;74(6):550-3 [8074036.001]
  • [Cites] Am J Cardiol. 1996 Sep 15;78(6):706-8 [8831416.001]
  • [Cites] Horm Metab Res. 1998 Aug;30(8):531-5 [9761386.001]
  • [Cites] Am J Cardiol. 1990 Oct 15;66(12):959-63 [2220619.001]
  • (PMID = 17297262.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  • [Other-IDs] NLM/ PMC2693545
  •  go-up   go-down


64. Buszman P, Zurakowski A, Gruszka A, Szkróbka I, Peszek-Przybyła E, Radwan K, Milewski K, Barteczko Z, Tendera M: Local paclitaxel delivery as a treatment of persistent, recurrent in-stent restenosis -- safety assessment. Kardiol Pol; 2006 Mar;64(3):268-72; discussion 273-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local paclitaxel delivery as a treatment of persistent, recurrent in-stent restenosis -- safety assessment.
  • Local intramural drug delivery (LDD -- Local Drug Delivery) seems to be an interesting alternative to drug-eluting stents (DES).
  • AIM: The aim of the study was to assess the safety and effectiveness of local intramural paclitaxel administration in the treatment of recurrent in-stent restenosis (ISR).
  • METHODS: Five patients were enrolled in the study (3 men, mean age 50+/-7 years) with at least a second episode of ISR within the same stent.
  • Control coronary angiography was performed six months after the procedure.
  • CONCLUSIONS: Local intramural paclitaxel delivery is a safe and effective method of ISR treatment.
  • [MeSH-major] Coronary Restenosis / drug therapy. Graft Occlusion, Vascular / prevention & control. Paclitaxel / administration & dosage
  • [MeSH-minor] Angioplasty, Balloon, Coronary / methods. Blood Vessel Prosthesis Implantation. Coated Materials, Biocompatible. Female. Follow-Up Studies. Humans. Injections, Intralesional / methods. Male. Middle Aged. Recurrence. Stents / adverse effects. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583327.001).
  • [ISSN] 0022-9032
  • [Journal-full-title] Kardiologia polska
  • [ISO-abbreviation] Kardiol Pol
  • [Language] eng; pol
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


65. De Waele M, Hendriks J, Lauwers P, Ortmanns P, Vanroelen W, Morel AM, Germonpré P, Van Schil P: Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg; 2006 Feb;29(2):240-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy.
  • OBJECTIVE: Remediastinoscopy is a valuable tool in restaging non-small cell lung cancer after induction therapy for mediastinal nodal involvement as it provides pathological evidence of response and may select patients for subsequent thoracotomy.
  • METHODS: From November 1994 to April 2003, a remediastinoscopy was performed in 32 patients (29 men, 3 women) after induction therapy for locally advanced non-small cell lung cancer.
  • Neoadjuvant chemotherapy was given in 26 patients and chemoradiotherapy in 6.
  • Median survival time for the whole group was 21 months (95% confidence interval [CI] 9-33).
  • Median survival time in patients with a positive remediastinoscopy was 7 months (95% CI 5-9), with a negative remediastinoscopy 41 months (95% CI 13-69), and with a false-negative remediastinoscopy 24 months (95% CI 5-43).
  • The difference between positive and negative remediastinoscopies was highly significant (p=0.003).
  • In the combined group of patients with positive and false-negative remediastinoscopies (n=17), median survival time was 8 months (95% CI 3-13).
  • CONCLUSIONS: Remediastinoscopy is a valuable restaging procedure after induction therapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386916.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Di Bonaventura C, Fattouch J, Mari F, Egeo G, Vaudano AE, Prencipe M, Manfredi M, Giallonardo AT: Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord; 2005 Sep;7(3):231-5
Hazardous Substances Data Bank. PIRACETAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes.
  • In this open-label prospective study, 19 patients (3 men, 16 women) affected by idiopathic generalized epilepsy were followed for at least 6 months following the introduction of levetiracetam.
  • Patients were categorized according to syndrome subtype: juvenile myoclonic epilepsy (8), juvenile absence epilepsy (5), childhood absence epilepsy (4), and eyelid myoclonia with absences (2).
  • Eleven patients received levetiracetam as monotherapy, eight as add-on therapy.
  • [MeSH-major] Anticonvulsants / therapeutic use. Epilepsy, Absence / drug therapy. Myoclonic Epilepsy, Juvenile / drug therapy. Piracetam / analogs & derivatives
  • [MeSH-minor] Electroencephalography. Female. Humans. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Idiopathic generalized epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162433.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants; 230447L0GL / etiracetam; ZH516LNZ10 / Piracetam
  •  go-up   go-down


67. Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z: Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother; 2005 Jul-Aug;39(7-8):1194-7
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We evaluated available cases with acute deterioration of renal function associated with zoledronic acid therapy drawn from the French Adverse Event Reporting System database until July 1, 2004.
  • RESULTS: We identified 4 men and 3 women between the ages of 52 and 70 years, with multiple myeloma or different types of metastatic cancer, who had experienced renal impairment during zoledronic acid therapy.
  • Four patients developed de novo acute renal failure, while the other 3 patients experienced acute deterioration of preexisting chronic renal failure.
  • Renal failure occurred after various durations of zoledronic acid therapy (1-120 days).
  • Our data confirm the previously reported risk factors for zoledronic acid-associated nephrotoxicity such as advanced cancer, multiple myeloma, preexisting renal failure, diabetes, hypertension, and concomitant use of nephrotoxic drugs.
  • CONCLUSIONS: These cases emphasize the need for regular monitoring of renal function during zoledronic acid treatment, with particular attention to patients with preexisting impaired renal function.
  • [MeSH-major] Bone Resorption / drug therapy. Diphosphonates / adverse effects. Imidazoles / adverse effects. Kidney Diseases / chemically induced. Kidney Diseases / epidemiology
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Adverse Drug Reaction Reporting Systems. Aged. Databases, Factual. Female. France / epidemiology. Humans. Male. Middle Aged. Multiple Organ Failure / chemically induced. Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956222.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


68. Diouf E, Diop AK, Beye MD, Kane O, Diop-Ndoye M, Boye CS, Ka-Sall B: [Acquired bacteraemias at the intensive care unit]. Dakar Med; 2003;48(1):34-40
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Bactériémies acquises dans un service de réanimation.
  • The emergence of multiresistant germs in ICUs, and the therapeutic difficulties that ensue, participate in the aggravation of the prognosis of these infections.
  • The aim of this work was to study the epidemiological aspects of acquired bacteraemias in ICU and the responsible germs sensitivity, to determine strategies of adequate antimicrobial treatment.
  • There were 16 men and 3 women.
  • The antimicrobial treatment was adapted in 84.2% of cases; the association ciprofloxacine-cefotaxime could be a good alternative in serious infections to Gram negative bacteria.
  • The role of this committee is to carry out microbiological surveillance, to recommand and make sure of the application of preventive measures against nosocomial infections, to promote the accessibility of antibiotics such as imipeneme, aztreonam, ceftazidime, vancomycine...., and to propose an appropriate antimicrobial treatment strategy; these measures could reduce notably the morbidity and mortality related to nosocomial infections in general and bactereamias in particular.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacteremia / drug therapy. Cross Infection / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776648.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Senegal
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


69. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, Premkumar A, Depaoli AM, Skarulis MC, Oral EA, Gorden P: Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism; 2004 Apr;53(4):513-9
Genetic Alliance. consumer health - Lipodystrophy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy.
  • We studied 14 patients (3 men and 11 women); 12 of who had generalized lipodystrophy (7 congenital, 5 acquired), and 2 patients had partial lipodystrophy.
  • Body composition and related parameters were evaluated at baseline and after 4 and 12 months of leptin therapy.
  • On treatment, serum leptin levels increased by 10-fold.
  • All patients reported a decrease in appetite on therapy.
  • Dual energy x-ray absorptiometry (DEXA) demonstrated significant decreases in fat mass (5.4 +/- 0.8 kg to 5.0 +/- 0.8 kg; P =.003) and lean body mass (51.2 +/- 3.2 kg to 48.3 +/- 3.4 kg; P =.003) at 4 months on therapy.
  • There was no impact of leptin therapy on bone mineral content, mineral density, and metabolism.
  • Changes in body composition occurred during the first 4 months of leptin therapy, but then stabilized and were sustained thereafter.
  • [MeSH-major] Body Composition / drug effects. Leptin / therapeutic use. Lipodystrophy / drug therapy
  • [MeSH-minor] Absorptiometry, Photon. Adolescent. Adult. Aged. Anthropometry / methods. Bone Density / drug effects. Bone and Bones / drug effects. Bone and Bones / metabolism. Eating / drug effects. Eating / physiology. Energy Metabolism / drug effects. Energy Metabolism / physiology. Female. Humans. Liver / anatomy & histology. Liver / drug effects. Male. Middle Aged. Prospective Studies. Rest

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045701.001).
  • [ISSN] 0026-0495
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


70. Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y: Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging; 2003 Oct;18(4):231-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The cases of 8 patients (3 men and 5 women; mean age 58.6 years, range 16 to 75 years) of clinically diagnosed MTX-induced pulmonary injury were reviewed.
  • During the average post-treatment follow-up period of 31.0 days (range 3 to 76 days), the opacities quickly improved after treatment in 6 patients; however, in 2 patients with pre-existing interstitial pneumonitis the opacities were refractory.
  • These opacities usually responded quickly to treatment; however, those patients with lung fibrosis at presentation may have worse prognosis.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Methotrexate / adverse effects. Pneumonia / chemically induced. Pneumonia / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Arthritis, Rheumatoid / drug therapy. Female. Follow-Up Studies. Humans. Lung / radiography. Lupus Erythematosus, Systemic / drug therapy. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14561908.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


71. Brewer RP, Parra A, Lynch J, Chilukuri V, Borel CO: Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. J Neurosurg Anesthesiol; 2001 Jul;13(3):202-6
Hazardous Substances Data Bank. MAGNESIUM SULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnesium sulfate therapy, standard in preventing seizures in preeclampsia, is under active investigation as a neuroprotective agent.
  • Patients were studied up to three times after SAH at prescribed time intervals.
  • Fourteen patients (11 women, 3 men; mean age 58 years) underwent 29 studies.
  • All patients underwent hypertensive, hypervolemic therapy.
  • Four patients developed cerebral vasospasm.
  • [MeSH-major] Anticonvulsants / therapeutic use. Blood Flow Velocity / drug effects. Cerebrovascular Circulation / drug effects. Intracranial Aneurysm / surgery. Magnesium Sulfate / therapeutic use. Subarachnoid Hemorrhage / physiopathology. Subarachnoid Hemorrhage / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Pressure / drug effects. Double-Blind Method. Female. Humans. Male. Middle Aged. Middle Cerebral Artery / drug effects. Middle Cerebral Artery / ultrasonography. Placebos. Postoperative Complications. Pulmonary Artery. Ultrasonography, Doppler, Transcranial. Vascular Resistance / drug effects. Vasospasm, Intracranial / etiology

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426093.001).
  • [ISSN] 0898-4921
  • [Journal-full-title] Journal of neurosurgical anesthesiology
  • [ISO-abbreviation] J Neurosurg Anesthesiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Placebos; 7487-88-9 / Magnesium Sulfate
  •  go-up   go-down


72. Crawford LM, Sinha RN, Odell RM, Comi RJ: Efficacy of insulin pump therapy: mealtime delivery is the key factor. Endocr Pract; 2000 May-Jun;6(3):239-43
MedlinePlus Health Information. consumer health - Diabetes Type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of insulin pump therapy: mealtime delivery is the key factor.
  • OBJECTIVE: To investigate, in a clinical setting, the effect of implementation of continuous subcutaneous insulin infusion (CSII) on control of plasma glucose and to identify factors associated with improved glycemic control in patients with type 1 diabetes mellitus.
  • METHODS: Nineteen patients (16 women and 3 men) with type 1 diabetes were studied retrospectively.
  • The subjects underwent follow-up for a mean of 14 months after conversion to CSII therapy.
  • CONCLUSION: In a clinical setting, CSII therapy in patients with type 1 diabetes improves glycemic control and lowers the total daily basal insulin dose without affecting weight.
  • Improved glycemic control was associated with a shift in insulin therapy from a high percentage of intermediate-acting insulin to a greater percentage of insulin administered in a meal-associated bolus form.
  • This study emphasizes the importance of mealtime insulin adjustment for tight glycemic control in patients using CSII therapy.
  • [MeSH-major] Diabetes Mellitus, Type 1 / drug therapy. Hypoglycemic Agents / administration & dosage. Hypoglycemic Agents / therapeutic use. Insulin / administration & dosage. Insulin / therapeutic use. Insulin Infusion Systems
  • [MeSH-minor] Adult. Blood Glucose / metabolism. Body Mass Index. Body Weight / drug effects. Eating / physiology. Female. Hemoglobin A, Glycosylated / metabolism. Humans. Injections, Subcutaneous. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endocr Pract. 2000 May-Jun;6(3):277-8 [11421546.001]
  • (PMID = 11421538.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Insulin
  •  go-up   go-down


73. Macon WR, Levy NB, Kurtin PJ, Salhany KE, Elkhalifa MY, Casey TT, Craig FE, Vnencak-Jones CL, Gulley ML, Park JP, Cousar JB: Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol; 2001 Mar;25(3):285-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They occurred in 11 women and 3 men with a median age of 36 years.
  • Disease distribution was primarily in the splenic red pulp and hepatic sinusoids, although liver infiltrates were largely periportal in four cases.
  • Eleven patients are dead, eight within a year of diagnosis, and two patients have maintained complete remissions after combination chemotherapy.
  • This group, along with the previously recognized gammadelta group, should be recognized as phenotypically heterogeneous subtypes of the same disease entity.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, T-Cell / pathology. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Receptors, Antigen, T-Cell, gamma-delta / metabolism. Splenic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11224598.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


74. Vergara G, Catanzariti D, Cozzi F, Accardi R, Spagnolli W, Cammilli L: Pharmacological atrial defibrillation via temporarily occluded coronary sinus: first clinical experience and implications for an implantable device. J Interv Card Electrophysiol; 2000 Jun;4(2):345-9
Hazardous Substances Data Bank. Propafenone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological atrial defibrillation via temporarily occluded coronary sinus: first clinical experience and implications for an implantable device.
  • The aim of this paper is to report the first experience of pharmacological atrial defibrillation in humans via a temporarily occluded coronary sinus.
  • PATIENTS AND METHODS: In 6 patients (3 women, 3 men; mean age 57.8y, min 31, max 71), with clinical recurrences of atrial fibrillation, an occlusive coronary venogram was carried out in order to establish the origin of the Vein of Marshall.
  • Atrial fibrillation was then induced by atrial pacing in all the patients and after an adequate waiting period to assure that the atrial fibrillation episode was persistent and stable, a bolus of a very low dose of an antiarrhythmic drug was delivered in 3-4 seconds into the temporarily balloon occluded coronary sinus near the orifice of the vein of Marshall.
  • For both the venogram and the pharmacological test a Baim-Turi (USCI-Bard, Billerica MA) or a Vueport (Cardima, Fremont CA) catheter was used.
  • CONCLUSIONS: Pharmacological atrial defibrillation with a minimal dose of an antiarrhythmic drug delivered near the orifice of the Vein of Marshall via the temporarily occluded coronary sinus is feasible and effective.
  • This new pharmacological atrial defibrillation can offer interesting opportunities in developing an implantable pharmacological atrial defibrillator.
  • [MeSH-major] Anti-Arrhythmia Agents / administration & dosage. Atrial Fibrillation / drug therapy. Infusion Pumps, Implantable. Propafenone / administration & dosage

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • Hazardous Substances Data Bank. Ibutilide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1982 Apr 29;306(17):1018-22 [7062992.001]
  • [Cites] Circulation. 1995 Oct 1;92(7):1954-68 [7671380.001]
  • [Cites] Am J Cardiol. 1998 Oct 16;82(8A):86N-91N [9809906.001]
  • (PMID = 10936000.001).
  • [ISSN] 1383-875X
  • [Journal-full-title] Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
  • [ISO-abbreviation] J Interv Card Electrophysiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Sulfonamides; 2436VX1U9B / ibutilide; 68IQX3T69U / Propafenone
  •  go-up   go-down


75. Rhoden EL, Morgentaler A: Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med; 2010 Jan;7(1 Pt 1):277-83
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
  • INTRODUCTION: Despite increasing medical interest in testosterone therapy (TTh) for men with testosterone deficiency (TD) there is limited information regarding subjective response rates and acceptability of medium- to long-term TTh in routine clinical practice.
  • AIM: To evaluate results in a consecutive series of men in clinical practice treated with TTh.
  • MATERIAL AND METHODS: A chart review was performed for a consecutive series of men for whom TTh was initiated over 1 year for a clinical diagnosis of TD.
  • A diagnosis of TD was based on the presence of symptoms and on laboratory evaluation indicating total testosterone (<300 ng/dL) or free testosterone (FT) (<1.5 ng/dL).
  • MAIN OUTCOME MEASURES: Percentage of men who completed 12 months of TTh, and symptomatic response rates.
  • RESULTS: There were 127 men included in the evaluation.
  • Improvements in erections, libido, energy, and/or mood were reported by 70% of men by 3 months.
  • Eighty men (63%) completed 12 months of TTh with subjective benefit (responders).
  • Treatment was discontinued in 34 (26.8%) who reported no major benefit (non-responders), and 13 (10.2%) were lost to follow-up.
  • Among men who discontinued TTh, 64.7%failed to report benefits by 3 months.
  • CONCLUSION: Approximately two-thirds of men with TD who begin TTh will experience symptomatic benefit and will complete at least 12 months of treatment.
  • [MeSH-major] Erectile Dysfunction / drug therapy. Hormone Replacement Therapy / psychology. Hypogonadism / drug therapy. Libido / drug effects. Patient Compliance / psychology. Testosterone / administration & dosage. Testosterone / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104673.001).
  • [ISSN] 1743-6109
  • [Journal-full-title] The journal of sexual medicine
  • [ISO-abbreviation] J Sex Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 3XMK78S47O / Testosterone; 7Z6522T8N9 / testosterone enanthate; M0XW1UBI14 / testosterone 17 beta-cypionate
  •  go-up   go-down


76. Meskhi IA, Sikharulidze EN, Natmeladze KV: [Percutaneous ethanol injection in combination with euthyrox suppressive therapy in the treatment of benign nodular goiter]. Georgian Med News; 2007 May;(146):11-3
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Percutaneous ethanol injection in combination with euthyrox suppressive therapy in the treatment of benign nodular goiter].
  • This study was designed to clarify the efficacy of combination of thyroid hormone (euthyrox) therapy and percutaneous ethanol injection (PEI) in benign nodular thyroid diseases.
  • 48 women and 7 men with thyroid nodules of the various sizes, structures and echogenecity have been included in the study group.
  • The control group consisted of 32 patients: 29 women and 3 men in the same age range as in the study group.
  • In both groups PEI procedure was performed but in the control group no thyroid hormone was added.
  • Thus, combination of thyroid hormone therapy and percutaneous ethanol injection (PEI) in treatment of patients with benign nodular goiter normalizes the size of a thyroid gland.
  • [MeSH-major] Ethanol / therapeutic use. Goiter, Nodular / drug therapy. Thyroxine / therapeutic use
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Injections, Subcutaneous. Male. Treatment Outcome

  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595451.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 3K9958V90M / Ethanol; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


77. Kubicka-Trzaska A, Romanowska-Dixon B: [Photodynamic therapy of circumscribed choroidal hemangioma]. Klin Oczna; 2006;108(4-6):209-13
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photodynamic therapy of circumscribed choroidal hemangioma].
  • PURPOSE: To evaluate efficacy of photodynamic therapy (PDT) with verteporfin in treatment of posterior pole symptomatic circumscribed choroidal hemangiomas.
  • MATERIAL AND METHODS: Four patients (3 men and 1 woman), 15-55 years old (mean age: 29 years) with circumscribed choroidal hemangiomas of the posterior pole, were examined.
  • The diagnosis of choroidal hemangioma was established on the base of clinical examination, A and B--scan ultrasound imaging, Doppler ultrasonography, fluorescein and indocyanine angiography results.
  • Tumour thickness before treatment ranged from 2.3-3.6 mm (mean thickness: 2.8 mm).
  • One course of PDT with verteporfin was performed in 3 cases, while in one patient PDT was performed four times.
  • CONCLUSIONS: Our preliminary results indicate that PDT with verteporfin is a safe and effective method of treatment for circumscribed choroidal hemangiomas, especially in patients with posterior pole location of the tumour.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma, Capillary / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Female. Fluorescein Angiography. Humans. Male. Middle Aged. Treatment Outcome. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019998.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


78. Krasagakis K, Samonis G, Maniatakis P, Georgala S, Tosca A: Bullous erysipelas: clinical presentation, staphylococcal involvement and methicillin resistance. Dermatology; 2006;212(1):31-5
Hazardous Substances Data Bank. CLOXACILLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bullous erysipelas represents a severe form of the disease.
  • OBJECTIVE: To evaluate the clinical and microbiological characteristics and treatment of bullous erysipelas.
  • METHODS: Patients with a diagnosis of bullous erysipelas who were treated at the Department of Dermatology, University Hospital of Heraklion, Crete, Greece, between the years 1996 and 2001 were retrospectively studied.
  • RESULTS: Fourteen patients (11 women, 3 men) with bullous erysipelas were evaluated.
  • The median duration of disease before hospital admission was 4 days.
  • The initial empirical antibiotic treatment included intravenous beta-lactams and was modified according to the sensitivities of the isolated strains.
  • The frequency of MRSA isolation suggests that beta-lactam antibiotics may not be sufficient for the treatment of bullous erysipelas anymore, at least in areas with a high incidence of MRSA strains.
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Cefuroxime / therapeutic use. Cloxacillin / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Methicillin / pharmacology. Methicillin / therapeutic use. Methicillin Resistance. Middle Aged. Netilmicin / therapeutic use. Penicillins / therapeutic use. Staphylococcus / drug effects. Staphylococcus / isolation & purification. Treatment Outcome. Vancomycin / therapeutic use

  • Genetic Alliance. consumer health - Erysipelas.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. NETILMICIN .
  • Hazardous Substances Data Bank. METHICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • [CommentIn] Dermatology. 2006;212(1):1-3 [16319465.001]
  • [CommentIn] Dermatology. 2007;214(2):191-2; author reply 192-3 [17341875.001]
  • (PMID = 16319471.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Penicillins; 4O5J85GJJB / Netilmicin; 6Q205EH1VU / Vancomycin; O1R9FJ93ED / Cefuroxime; O6X5QGC2VB / Cloxacillin; Q91FH1328A / Methicillin
  •  go-up   go-down


79. Bourgeois H, Billiart I, Chabrun V, Chieze S, Lemerre D, Germain T, Ferrand V, Meurice JC, Daban A, Tourani JM: Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. Am J Clin Oncol; 2004 Feb;27(1):89-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ifosfamide (I) has also been approved for NSCLC treatment.
  • In this study, one cycle of chemotherapy combined the following: ifosfamide: 3 g/m2 fixed dose (24-hour intravenous infusion) combined with mesna, day 1; gemcitabine: starting dose 1,000 mg/m2/d, escalating by 250 mg/m2 increments, days 1 and 15; cisplatin: starting dose 80 mg/m2, subsequently 100 mg/m2, day 15; in cohorts of at least 3 patients.
  • DLT was evaluated after the first chemotherapy cycle.
  • Thirty-three patients (30 men, 3 women) with stage III (14 patients)/IV (19 patients) NSCLC were treated at eight dose levels, receiving 109 cycles of chemotherapy.
  • Sixteen of 33 patients with measurable/evaluable disease had an objective response including two complete responses.
  • In conclusion, GIP chemotherapy is safe and appears to be active in patients with NSCLC.
  • A confirmatory phase II study is currently under way, before a phase III trial of GIP versus GP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758140.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


80. Chodorowski Z, Anand JS, Rutkowski P: [Neuroleptic malignant syndrome]. Przegl Lek; 2003;60(4):299-301
MedlinePlus Health Information. consumer health - Respiratory Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroleptic malignant syndrome].
  • Neuroleptic malignant syndrome (NMS) is the most dangerous side effect of phenothiazines therapy.
  • In the period of time from 1995 to 2002 in the Intensive Toxicological Unit there were five patients, 3 men and 2 women, aged from 25 to 62 (average 44.2) years-old, admitted from the regional inpatients psychiatric units with the diagnosis of pneumonia and/or sepsis.
  • The neuroleptic drug was withdrawn and intensive supportive care with administration of bromocriptine (15-20 mg/24 h) was provided.
  • None one of the doctors told the patients about the possibility of NMS during phenothiazines therapy.
  • [MeSH-major] Bromocriptine / therapeutic use. Dopamine Agonists / therapeutic use. Neuroleptic Malignant Syndrome / complications. Respiratory Insufficiency / etiology. Respiratory Insufficiency / therapy

  • Genetic Alliance. consumer health - Neuroleptic malignant syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14569909.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


81. Kinuya K, Matano S, Nakashima H, Taki S: Scintigraphic prediction of therapeutic outcomes of splenectomy in patients with thrombocytopenia. Ann Nucl Med; 2003 Apr;17(2):161-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scintigraphic prediction of therapeutic outcomes of splenectomy in patients with thrombocytopenia.
  • METHODS: Platelet scintigraphy was performed in five patients (2 women, 3 men, mean age 48 years) before splenectomy.
  • Four patients were diagnosed with idiopathic thrombocytopenic purpura and one with hypersplenism due to portal hypertension caused by intrahepatic chemotherapy against metastatic liver tumors of rectal cancer.
  • CONCLUSION: The results of this study indicate that platelet scintigraphy is of value in predicting the therapeutic efficacy of splenectomy in patients with thrombocytopenia.
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Male. Middle Aged. Platelet Count. Predictive Value of Tests. Prognosis. Radiopharmaceuticals. Spleen / blood supply. Spleen / radionuclide imaging. Spleen / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12790368.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 3B744AG22N / Technetium Tc 99m Exametazime
  •  go-up   go-down


82. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P: Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology; 2003 Jan;37(1):60-4
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early interferon (IFN) therapy prevents viral persistence in acute hepatitis C, but in view of the resulting costs and morbidity patients who really need therapy have to be identified.
  • Twelve consecutive patients with acute hepatitis C (9 women, 3 men, mean age: 39.5 +/- 18.8 y, genotype 1: 7, genotype 3a: 3, 2 could not be genotyped) were studied.
  • The sources of infection were medical procedures in 6, sexual transmission in 3, and intravenous drug abuse in 3 patients.
  • The time from infection to clinical symptoms was 43.3 +/- 8.6 (mean +/- SD) days.
  • The time from exposure to HCV-RNA negativity was 77.4 +/- 25.3 and from the first symptoms was 34.7 +/- 22.1 days.
  • Two of them became sustained responders to treatment initiated after a 6-week observation period.
  • The 2 remaining patients were not treated (one because of contraindications for IFN, the other declined therapy) and are still HCV-RNA positive.
  • IFN therapy appears only needed in patients who fail to clear the virus within 35 days after onset of symptoms.
  • By this approach, IFN therapy was not necessary in two thirds of patients with acute hepatitis C.
  • [MeSH-major] Hepacivirus / genetics. Hepatitis C / diagnosis. Hepatitis C / virology. Viral Load
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Alanine Transaminase / blood. Female. Genotype. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. RNA, Viral / analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2003 Jun;37(6):1495-6; author reply 1496 [12774030.001]
  • (PMID = 12500189.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


83. Di Martino V, Boudjema H, Delacour T, Cazier A, Caron C, Coutarel P, Dumouchel P, Cadranel JF: Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin. Clin Infect Dis; 2001 Mar 1;32(5):830-1
Hazardous Substances Data Bank. AMANTADINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.
  • Seven women and 3 men infected with hepatitis C virus, all of whom had failed to respond to therapy with either IFN-alpha or IFN and ribavirin, were treated with 200 mg/day of amantadine hydrochloride for 12 months.
  • These results suggest that amantadine hydrochloride should not be used as monotherapy for patients who do not respond to treatment with IFN-alpha and/or ribavirin.
  • [MeSH-major] Amantadine / therapeutic use. Antiviral Agents / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Ribavirin / therapeutic use
  • [MeSH-minor] Alanine Transaminase / blood. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11229855.001).
  • [ISSN] 1058-4838
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin; BF4C9Z1J53 / Amantadine; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


84. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK: Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis; 2008 May;51(5):724-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.
  • SETTING & PARTICIPANTS: 10 patients (3 men) with biopsy-proven IgA nephropathy and persistent proteinuria despite angiotensin-converting enzyme-inhibitor or angiotensin receptor blocker therapy in a tertiary referral center.
  • RESULTS: After calcitriol treatment, there was a significant overall decrease in proteinuria with time by using a general linear model with repeated measures (P = 0.03).
  • LIMITATIONS: This small study is uncontrolled and does not examine the long-term effect of calcitriol therapy.
  • CONCLUSION: Twice-weekly oral calcitriol has a modest antiproteinuric effect in patients with IgA nephropathy and persistent proteinuria despite angiotensin-converting enzyme-inhibitor or angiotensin receptor blocker therapy.
  • [MeSH-major] Calcitriol / administration & dosage. Glomerulonephritis, IGA / complications. Proteinuria / drug therapy. Renal Agents / administration & dosage


85. Riadh BS, El Atat R, Sfaxi M, Derouiche A, Kourda N, Chebil M: Clinical presentation and outcome of bladder schistosoma-unrelated squamous cell carcinoma: report on 33 consecutive cases. Clin Genitourin Cancer; 2007 Sep;5(6):409-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective review is helpful in understanding the epidemiologic aspects, pathogenesis, and treatment and prognosis of schistosoma-unrelated SCC.
  • PATIENTS AND METHODS: Between 1987 and 2002, 30 men and 3 women had been treated for pure SCC of the bladder, not related to bilharzias.
  • They constitute 1.2% of all bladder tumors.
  • Twenty-one patients underwent radical cystectomy, followed by chemotherapy in 2 cases.
  • At a mean follow-up of 5 years, 14 patients (66.6%) died of locoregional disease, with associated metastasis in 5 cases.
  • Seven patients (33.3%) are alive without any evidence of disease.
  • CONCLUSION: The unrelated SCC has an unfavorable prognosis, mostly caused by the locally advanced disease at the time of presentation.
  • The transfer of novel chemotherapy regimens and preoperative radiation therapy should be considered because pelvic recurrences are the leading cause of progression in SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / parasitology. Schistosoma haematobium / isolation & purification. Schistosomiasis haematobia / parasitology. Urinary Bladder Neoplasms / parasitology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956717.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Curioso WH, Kurth AE: Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru. BMC Med Inform Decis Mak; 2007 Sep 12;7:24
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this paper is to report on perceptions towards use of information and communication technologies as a means to support antiretroviral medication adherence and HIV transmission risk reduction.
  • RESULTS: 31 HIV-positive individuals in Lima were interviewed (n = 28 men, 3 women).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2000 Jan 8;320(7227):114-6 [10625273.001]
  • [Cites] J Med Internet Res. 2004 Sep 29;6(3):e32 [15471758.001]
  • [Cites] J Health Commun. 2000;5 Suppl:47-59 [11010356.001]
  • [Cites] SIECUS Rep. 1998 Jun-Jul;26(5):14 [12348570.001]
  • [Cites] AIDS Educ Prev. 2002 Feb;14(1):51-61 [11900110.001]
  • [Cites] AIDS. 2002 Jun 14;16(9):1271-7 [12045493.001]
  • [Cites] Int J STD AIDS. 2005 Jan;16(1):19-22 [15705267.001]
  • [Cites] J Med Libr Assoc. 2005 Oct;93(4):431-9 [16239938.001]
  • [Cites] J Am Pharm Assoc (2003). 2005 Sep-Oct;45(5):625-8 [16295649.001]
  • [Cites] J Subst Abuse Treat. 2006 Apr;30(3):237-43 [16616168.001]
  • [Cites] Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S103-7 [16769438.001]
  • [Cites] Health Psychol. 2006 Jul;25(4):462-73 [16846321.001]
  • [Cites] JAMA. 2006 Aug 9;296(6):679-90 [16896111.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):855-8 [16905790.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e11 [17326701.001]
  • [Cites] Sex Transm Dis. 2007 May;34(5):309-13 [17016236.001]
  • [Cites] Sex Transm Infect. 2006 Aug;82(4):311-6 [16877581.001]
  • [Cites] Int J Med Inform. 2002 Nov 12;65(3):169-77 [12414016.001]
  • [Cites] MMWR Recomm Rep. 2003 Jul 18;52(RR-12):1-24 [12875251.001]
  • [Cites] Lancet. 2004 Jul 3-9;364(9428):6-8 [15234835.001]
  • [Cites] JAMA. 2000 Jul 26;284(4):447-9 [10904507.001]
  • (PMID = 17850656.001).
  • [ISSN] 1472-6947
  • [Journal-full-title] BMC medical informatics and decision making
  • [ISO-abbreviation] BMC Med Inform Decis Mak
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW007551; United States / FIC NIH HHS / TW / 5D43TW007551
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Other-IDs] NLM/ PMC2048945
  •  go-up   go-down


87. Barqawi AB, Myers JB, O'Donnell C, Crawford ED: The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU Int; 2007 Oct;100(4):853-7
Hazardous Substances Data Bank. Tamsulosin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
  • OBJECTIVE: To assess the effect of tamsulosin on the Sexual Health Inventory for Men (SHIM) score in men diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
  • PATIENTS AND METHODS: Analysis from the national database of a programme of the Prostate Cancer Educational Council identified 7974 men who completed the American Urologic Association Symptom Score (AUA-SS) and SHIM questionnaires.
  • The patients were divided into three groups; group 1, men taking tamsulosin; group 2, men on other prescription medications for treating BPH symptoms; and group 3, men not currently taking any BPH medications.
  • RESULTS: The median age of the men was 60 years.
  • In groups 1, 2 and 3, (234, 291 and 7449 men, respectively) the mean (sd) AUA-SS was 13.0 (7.2), 12.1 (7.2) and 6.9 (5.8), and the mean SHIM scores 11.7 (6.8), 12.7 (6.5) and 15.9 (6.0), respectively.
  • Adjusting for the AUA-SS, men in group 1 on tamsulosin had a significantly higher SHIM score with increasing AUA-SS score than men on other medications (P < 0.01), offsetting the negative correlation between the AUA-SS and SHIM (P < 0.01).
  • Moreover, men in group 1 were more likely to have a higher AUA-SS and lower SHIM score than men in the other two groups, suggesting more severe symptoms in these men.
  • CONCLUSIONS: Men taking tamsulosin to treat LUTS appear to be at an advantage over men taking other alpha-blockers when the effect of LUTS on sexual health is considered.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Erectile Dysfunction / prevention & control. Prostatic Hyperplasia / drug therapy. Prostatism / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Aged. Cross-Sectional Studies. Humans. Male. Middle Aged. Quality of Life. Regression Analysis. Severity of Illness Index. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662074.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


88. Sidat M, Fairley C, Grierson J: Experiences and perceptions of patients with 100% adherence to highly active antiretroviral therapy: a qualitative study. AIDS Patient Care STDS; 2007 Jul;21(7):509-20
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experiences and perceptions of patients with 100% adherence to highly active antiretroviral therapy: a qualitative study.
  • A decade has passed since the introduction of highly active antiretroviral therapy (HAART) as standard of care for HIV/AIDS patients.
  • Thus, we purposefully recruited for in-depth interviews 10 participants (7 men and 3 women) with 100% adherence to HAART (>/=6 months previous to the interviews).
  • [MeSH-major] Antiretroviral Therapy, Highly Active / psychology. HIV Infections / drug therapy. Patient Compliance / psychology


89. Elkihal L, Ajana FZ, Seddik H, Essamri W, Benelbarhdadi I, Afifi R, Benazzouz M, Essaid A, Kettani F: [Advances in the diagnosis and management of gastrointestinal tumours: 5 cases]. Sante; 2005 Oct-Dec;15(4):271-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advances in the diagnosis and management of gastrointestinal tumours: 5 cases].
  • [Transliterated title] Nouvelles acquisitions diagnostiques et thérapeutiques sur les tumeurs stromales digestives: à propos de cinq cas.
  • Options for diagnosis and treatment have developed rapidly in recent years.
  • CASES: The study concerns 5 patients: 3 men and 2 women, with a mean age at diagnosis of 39.8 years.
  • Liver metastasis was identified at initial diagnosis for one patient.
  • All the patients underwent surgical resection for GIST, and one received chemotherapy.
  • No patient received imatinib treatment.
  • Diagnosis and treatment options for patients are described in a discussion of the recent advances in the field.
  • [MeSH-major] Gastrointestinal Stromal Tumors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16478708.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


90. Vishne T, Amiaz R, Grunhaus L: Promethazine for the treatment of agitation after electroconvulsive therapy: a case series. J ECT; 2005 Jun;21(2):118-21
Hazardous Substances Data Bank. Promethazine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promethazine for the treatment of agitation after electroconvulsive therapy: a case series.
  • OBJECTIVES: Agitation after electroconvulsive therapy (ECT) is observed in approximately 7% of patients.
  • In the current study, we present a series of 8 patients who reacted to ECT with severe agitation and improved under the treatment of promethazine.
  • METHODS: Eight patients were included (5 women, 3 men), ages 22 to 77 years.
  • All patients were prescribed either 25 to 50 mg of promethazine 2 hours before the treatment to avoid agitation.
  • RESULTS: All 8 patients suffered from extreme agitation after ECT treatment, and 7 required the administration of intravenous midazolam.
  • [MeSH-major] Electroconvulsive Therapy / adverse effects. Histamine H1 Antagonists / therapeutic use. Promethazine / therapeutic use. Psychomotor Agitation / etiology. Psychomotor Agitation / prevention & control
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905755.001).
  • [ISSN] 1095-0680
  • [Journal-full-title] The journal of ECT
  • [ISO-abbreviation] J ECT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H1 Antagonists; FF28EJQ494 / Promethazine
  •  go-up   go-down


91. Zhang YJ, Chen MS, Liang HH, Xu L, Zhang YQ: [Clinicopathologic features and treatment outcomes of primary hepatic lymphoma: a report of four cases]. Ai Zheng; 2005 Mar;24(3):365-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features and treatment outcomes of primary hepatic lymphoma: a report of four cases].
  • This article was to investigate clinicopathologic features and treatment of PHL.
  • RESULTS: Of the 4 patients, 3 were men, and 1 was woman, with a median age of 53 years old; 3 had single focus, and 1 had multi-foci.
  • All patents were positive for HBV antigen, 3 were misdiagnosed preoperatively, and 1 had no clear diagnosis before operation.
  • Two patients received resection, and 2 received biopsy; all patients received adjuvant chemotherapy postoperatively.
  • Resection followed by adjuvant chemotherapy with CHOP regiment seems to be the best option for PHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatectomy. Hodgkin Disease / therapy. Liver Neoplasms / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnostic Errors. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Hepatitis Antigens / analysis. Humans. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757544.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis Antigens; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


92. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res; 2003 Dec 1;9(16 Pt 1):5880-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Eligible patients were those with SCLC who either had chemotherapy-naive extensive-stage or had SCLC in a sensitive relapse.
  • RESULTS: Nineteen patients with SCLC entered on the study, including 16 men and 3 women.
  • Nine patients had previously untreated extensive-stage disease and 10 patients had sensitive relapse.
  • There were no objective responses; however, one patient with sensitive-relapse disease had prolonged stabilization of disease (>3 months) while on imatinib therapy.
  • The median time to progression was 0.8 months (range, 0.6-1.3 months) and 1.2 months (range, 0.2-4.1 months) in the previously untreated and sensitive-relapse groups, respectively.
  • Tumor tissue samples from 4 (21%) of the 19 patients had the KIT receptor (CD117).
  • CONCLUSIONS: There was no observed antitumor activity in this limited Phase II trial of patients with SCLC, of which only a few tumors showed expression of the imatinib target.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / drug effects. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Disease Progression. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5825-8 [14676102.001]
  • (PMID = 14676110.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


93. Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, Auteri A: Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther; 2002 Nov;72(5):556-61
Hazardous Substances Data Bank. Adenosine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia.
  • BACKGROUND AND OBJECTIVE: Nimodipine is a dihydropyridine calcium channel blocker used in the treatment of ischemic damage in subarachnoid hemorrhage.
  • METHODS: Twelve patients with cerebral ischemia (9 men and 3 women; mean age, 68.8 +/- 11.2 years; mean weight, 67.9 +/- 9.3 kg) were admitted to the study.
  • RESULTS: Both the intravenous and oral administrations induced a statistically significant increase in plasma adenosine levels (P <.001), which appeared to be related to the dose and route of drug administration.
  • The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319.6 +/- 38.9 ng/mL at the first sampling time; area under the curve (AUC), 239 +/- 25 ng. h/mL; and terminal half-life, 3.12 +/- 0.97 hours.
  • After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng. h/mL.
  • CONCLUSIONS: Our data indicate that the administration of nimodipine induces an increase in plasma adenosine levels, and we hypothesize that the drug activity could be associated, at least partially, with adenosine mediation.
  • [MeSH-major] Adenosine / blood. Brain Ischemia / drug therapy. Calcium Channel Blockers / pharmacokinetics. Nimodipine / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12426519.001).
  • [ISSN] 0009-9236
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 57WA9QZ5WH / Nimodipine; K72T3FS567 / Adenosine
  •  go-up   go-down


94. Díez JJ, Iglesias P: Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest; 2002 Oct;25(9):773-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin analogs in the treatment of medullary thyroid carcinoma.
  • The medical therapy for advanced or metastatic medullary thyroid carcinoma has not been fully established.
  • Somatostatin analogs have been used with variable success in the therapy of a few patients with medullary thyroid carcinoma.
  • In the present study, we evaluated the effects of somatostatin analog therapy on calcitonin (ct) and carcinoembryonic antigen in patients with advanced medullary thyroid carcinoma.
  • Five patients (2 men and 3 women, aged 35-57 yr) with post-operative recurrent medullary thyroid carcinoma received somatostatin analog therapy for 12 weeks.
  • Serum samples for ct and carcinoembryonic antigen were obtained at 0, 1, 2, 4, 8 and 12 weeks of therapy.
  • Therapy was well-tolerated in general, with minimal side-effects.
  • One patient died after the first month of therapy because of advanced disease.
  • Another patient showed normalization of his ct and carcinoembryonic antigen concentrations at the second week of therapy, maintaining elevated values thereafter.
  • One patient with positive (111)In-pentetreotide scan, showed no uptake after somatostatin analog therapy.
  • In conclusion, therapy with different formulations of octreotide and lanreotide does not seem to modify serum concentrations of ct and carcinoembryonic antigen in patients with recurrent medullary thyroid carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Medullary / drug therapy. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Calcitonin / blood. Carcinoembryonic Antigen / blood. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 1987 Oct;22(8):938-42 [2891186.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):402-8 [8625251.001]
  • [Cites] Henry Ford Hosp Med J. 1989;37(3-4):151-3 [2576951.001]
  • [Cites] Cancer. 2001 May 1;91(9):1797-808 [11335906.001]
  • [Cites] Q J Nucl Med. 1995 Dec;39(4 Suppl 1):134-6 [9002772.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Ann Endocrinol (Paris). 1989;50(6):483-8 [2635843.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Jun;64(6):1313-9 [2883196.001]
  • [Cites] Clin Nucl Med. 1988 Apr;13(4):260-3 [2897264.001]
  • [Cites] Horm Metab Res. 1989 Oct;21(10):584-6 [2807148.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2417-20 [9661621.001]
  • [Cites] Surgery. 1986 Dec;100(6):962-70 [2431492.001]
  • [Cites] Horm Metab Res. 1988 Dec;20(12):773-5 [2906036.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1114-8 [8780551.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Aug;33(2):261-9 [1977536.001]
  • [Cites] Med Klin (Munich). 1995 Feb 15;90(2):63-6 [7708002.001]
  • [Cites] Horm Metab Res Suppl. 1993;27:44-7 [8330871.001]
  • [Cites] Yale J Biol Med. 1992 Sep-Oct;65(5):505-18; discussion 531-6 [1364090.001]
  • [Cites] Neth J Med. 1992 Jun;40(5-6):240-3 [1436261.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):983-8 [10720027.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Feb;36(2):183-6 [1568350.001]
  • (PMID = 12398235.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Carcinoembryonic Antigen; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; 9007-12-9 / Calcitonin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


95. Aste N, Fumo G, Contu F, Aste N, Biggio P: Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol; 2002 Jul;47(1):146-7
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a series of 9 patients, 6 men and 3 women, who presented nail hyperpigmentation arising between 6 and 24 months from the start of hydroxyurea therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hematologic Neoplasms / drug therapy. Hydroxyurea / adverse effects. Hyperpigmentation / chemically induced. Nail Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12077597.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


96. Shammas NW, Harris ML, McKinney D, Hauber WJ: Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers. Clin Cardiol; 2001 Dec;24(12):786-7
Hazardous Substances Data Bank. DIGOXIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 8 consecutive patients with IDCM (5 men, 3 women) who had normalization of LVEF following beta-blocker treatment, digoxin was withdrawn as part of an office protocol. and LVEF was followed.
  • CONCLUSION: These data provide potential evidence that digoxin withdrawal can result in a small but significant reduction in LVEF in patients with IDCM who had normalization of LVEF after treatment with beta blockers.
  • Mean LVEF, however, remained within normal (> 50%) on beta-blocker therapy and without digitalis.
  • [MeSH-major] Angiotensin-Converting Enzyme Inhibitors / pharmacology. Cardiomyopathy, Dilated / drug therapy. Digoxin / pharmacology. Ventricular Function, Left / drug effects
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Aged. Female. Humans. Male. Middle Aged. Stroke Volume / drug effects

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Dilated Cardiomyopathy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11768743.001).
  • [ISSN] 0160-9289
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 73K4184T59 / Digoxin
  •  go-up   go-down


97. Smit JW, Janssen YJ, Lamb HJ, van der Wall EE, Stokkel MP, Viergever E, Biermasz NR, Bax JJ, Vliegen HW, de Roos A, Romijn JA, Roelfsema F: Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab; 2001 Oct;86(10):4638-43
MedlinePlus Health Information. consumer health - Heart Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass.
  • We therefore randomly assigned 22 patients with ischemic cardiac failure (left ventricular ejection fraction, <40%; 19 men and 3 women; mean age, 64 yr) to receive 6 months of unblinded therapy with recombinant human GH (2.0 IU/d) or no treatment.
  • Primary end points were left ventricular ejection fraction and left ventricular mass.
  • Left ventricular end-diastolic volume, left ventricular end-systolic volume, and myocardial perfusion, both at rest and during exercise, were assessed as well.
  • Cardiac imaging techniques were electrocardiographically gated single photon emission computer tomography and magnetic resonance imaging.
  • IGF-I and IGF-binding protein-3 increased significantly after recombinant human GH treatment (+24% and +58%, respectively) compared with control values (-14% and +5%; P < 0.05).
  • Left ventricular ejection fraction, left ventricular end-diastolic volume, left ventricular end-systolic volume, left ventricular mass, and myocardial perfusion were not influenced by recombinant human GH therapy.
  • We conclude that 6 months of recombinant human GH treatment in patients with ischemic cardiac failure had no beneficial effect on left ventricular function and mass.
  • [MeSH-major] Growth Hormone / therapeutic use. Heart Failure / drug therapy. Hypertrophy, Left Ventricular / prevention & control. Myocardial Ischemia / drug therapy. Ventricular Function, Left / drug effects
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2001 Oct;86(10):4635-7 [11600517.001]
  • (PMID = 11600518.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


98. Neglia D, Sambuceti G, Giorgetti A, Bartoli M, Salvadori P, Sorace O, Puccini G, L'Abbate A, Parodi O: Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure. J Cardiovasc Pharmacol; 2000 Dec;36(6):744-50
Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure.
  • We assessed the safety of long-term combination therapy of verapamil and enalapril and its effects on both left ventricular function and myocardial perfusion compared with enalapril alone in 18 patients with DCM (15 men, 3 women; mean age, 50+/-9 years) without overt heart failure (NYHA class I-II).
  • At baseline and after 6 months of randomized treatment with either enalapril (10-20 mg) (nine patients, group 1) or enalapril (10-20 mg) and verapamil (120-240 mg) (nine patients, group 2), left ventricular function was assessed at rest, during handgrip, and during bicycle exercise by equilibrium radionuclide angiography.
  • Mean MBF was measured at rest and after dipyridamole by positron emission tomography (PET) and 13N-ammonia as a flow tracer.
  • During treatment, no adverse events occurred in either group.
  • After 6 months there was no significant difference in the main study variables either between the two groups or within each group before and after treatment.
  • Long-term combination therapy with verapamil and enalapril is safe in patients with DCM without overt heart failure.
  • Despite no favorable effect on myocardial perfusion, combined treatment prevented deterioration of left ventricular function, similarly to enalapril alone.
  • [MeSH-major] Calcium Channel Blockers / pharmacology. Cardiomyopathy, Dilated / physiopathology. Coronary Circulation / drug effects. Ventricular Function, Left / drug effects. Verapamil / pharmacology
  • [MeSH-minor] Cardiac Output / drug effects. Double-Blind Method. Exercise Test. Female. Heart / radionuclide imaging. Heart Failure / physiopathology. Humans. Male. Middle Aged. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Dilated Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11117374.001).
  • [ISSN] 0160-2446
  • [Journal-full-title] Journal of cardiovascular pharmacology
  • [ISO-abbreviation] J. Cardiovasc. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; CJ0O37KU29 / Verapamil
  •  go-up   go-down


99. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E: Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology; 2000 May;118(5):821-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Cure of Helicobacter pylori infection may lead to complete remission of associated low-grade mucosa-associated lymphoid tissue (MALT) lymphoma in stage EI.
  • Patients received 40 mg omeprazole and 750 mg amoxicillin 3 times per day for 14 days.
  • Polymerase chain reaction (PCR) was used to detect rearrangement of immunoglobulin heavy-chain genes before treatment and during follow-up.
  • RESULTS: Five patients (3 men, 2 women; mean age, 65 years; range, 42-79 years) were studied. H. pylori was not detected by culture, histology, serology, or PCR.
  • Treatment resulted in the cure of H. heilmannii infection in each case and complete histological and endoscopic remission of the tumors.
  • Three of 5 patients showed monoclonal B cells before treatment, 2 of whom remained PCR positive.
  • [MeSH-major] Helicobacter. Helicobacter Infections / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10784580.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


100. Ito M, Kimura H, Yoshida K, Kimura Y, Ozaki N, Kurita K: Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol; 2010 Mar-Apr;33(2):79-83
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.
  • OBJECTIVES: The effect of milnacipran for the treatment of chronic pain in the orofacial region, including burning mouth syndrome (BMS) and atypical odontalgia (AO), was assessed while accounting for the influence of concurrent depressive symptoms on the pain-relieving effect.
  • METHODS: Milnacipran was administered for 12 weeks to 36 patients with chronic pain in the orofacial region (3 men and 29 women, aged between 22 and 76 years with a mean age of 59 years).
  • Pain was assessed using the visual analog scale, and symptoms of depression were evaluated using the Hamilton Depression Rating Scale at baseline and at weeks 1, 2, 4, 6, 8, 10, and 12 of the study treatment.
  • The visual analog scale score significantly decreased after the 12-week treatment, and it showed a similar time course of decline irrespective of concurrent depressive symptoms during the 12 weeks.
  • CONCLUSIONS: Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression.
  • The present results suggested that milnacipran may be an effective agent for treatment of such disorders.
  • [MeSH-major] Adrenergic Uptake Inhibitors / therapeutic use. Burning Mouth Syndrome / drug therapy. Cyclopropanes / therapeutic use. Depression / drug therapy. Facial Pain / drug therapy. Serotonin Uptake Inhibitors / therapeutic use. Toothache / drug therapy
  • [MeSH-minor] Adult. Aged. Chronic Disease. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Neuropharmacol. 2010 Sep-Oct;33(5):270 [20864840.001]
  • (PMID = 20375656.001).
  • [ISSN] 1537-162X
  • [Journal-full-title] Clinical neuropharmacology
  • [ISO-abbreviation] Clin Neuropharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Cyclopropanes; 0 / Serotonin Uptake Inhibitors; G56VK1HF36 / milnacipran
  •  go-up   go-down






Advertisement